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1.1 Tight junctions 
As one of the four basic tissue types, epithelia are the interface of inner and outer 
environment of the body. In this, they function both as a protective barrier and 
transport-mediators across the cell layer. For molecules, there are two ways of passing 
through epithelia: transcellular transport by specific transmembrane proteins and para-
cellular transport which is a passive movement across the space between adjacent 
cells (Figure 1a).  
Based on the proportion of transepithelial flux via the paracellular route, epithelia could 
be classified as tight epithelia, in which transcellular transport behaves as a major 
pathway for example in distal segments of the intestine, and leaky epithelia as typically 
found in the proximal intestine, in which the paracellular pathway becomes a path of 
greater importance (Claude and Goodenough, 1973).  
The function of the paracellular route is mainly achieved by the junctional complex 
between polarized epithelial cells (Denker and Nigam, 1998), comprising four struc-
tures, from the basal to the apical side in order, desmosomes, gap junctions, adherens 
junctions and tight junctions (TJ, Zonula occludens) (Figure 1b, c). Desmosomes are 
small contact regions between lateral membranes of neighbouring cells. Gap junctions 
are connections between contiguous cells, which allow the exchange of molecules 
smaller than 1000 Da. Adherens junctions are connected to the actin skeleton and 
attach neighbouring cells to each other.  
Of all these four components of the junctional complex, the TJ holds the most apical 
position between the lumen and the intracellular space and is considered as determi-
nant of the paracellular transport. Therefore, on one hand, it behaves as a “fence” that 
divides the apical membrane from the basolateral membrane of polarized cells and 
regulates the movement of membrane constituents from apical side to basolateral do-
main (Diamond, 1977), and on the other hand, the TJ also has a “gate function” that 
controls the passage of water, ions, small water-soluble molecules and – under certain 





Figure 1 Transport pathways and junctional complex. (a) Schematic diagram 
of the transcellular and paracellular pathway through epithelia. (b) Schematic 
representation of intestinal epithelial cells. (c) Electron micrograph of the junc-
tional complex in murine intestinal epithelial cells. Scale bar = 200 nm. Mv = 
microvilli, TJ = tight junction (circled), AJ = adherens junction, DS = desmo-
some. (Tsukita et al., 2001). 
 
The morphological structure of the TJ was first described over half a century ago as 
fused outer membranes of adjacent cells (Farquhar and Palade, 1963). With the appli-
cation of freeze fracture electron microscopic technique, the belt-like meshwork 
strands of TJs were exhibited (Staehelin et al., 1969), which should refer to the TJs 
between two epithelial cells, namely the bicellular TJ (bTJ) (as marked in Figure 2). In 
the region where three or more cells meet, TJ strands are differently organized and 
termed the tricellular TJ (tTJ). Here the most apical bTJs converge and extend to the 
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basal direction forming a 10 nm wide and 1 μm long central tube (Staehelin, 1973) 
(Figure 2, arrow heads), which since then has been considered to be a structural weak 
point of the paracellular barrier. 
 
 
Figure 2 Schematic drawing (a) and freeze fracture electron micrograph (b) 
of the bTJ (transverse bracket) and the tTJ (vertical bracket). The central tube 
is pointed by a group of arrow heads. (modified from Staehelin, 1973). 
 
Until now, a number of TJ proteins have been discovered and are grouped into four 
families: (1) the claudin family including 27 members in mammals (Mineta et al., 2011), 
(2) junctional adhesion molecules (JAM) (Martin-Padura et al., 1998), (3) TJ-associ-
ated MARVEL proteins (TAMP) comprising three members, occludin (Furuse et al., 
1993), tricellulin (Ikenouchi et al., 2005), and myelin and lymphocyte and related pro-
teins for vesicle trafficking and membrane link (MARVEL) D3 (Steed et al., 2009, 
Raleigh et al., 2010), and (4) the angulin family containing three members (Higashi et 
al., 2013).  
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Functionally, claudins could be roughly divided into four sub-groups: (i) cation-selective 
channel-forming claudins (e.g. claudin-2, -10b, -15), (ii) anion-selective channel-form-
ing claudins (e.g. claudin-10a, -17), (iii) water-channel-forming claudins (claudin-2, -15) 
and (iv) barrier-forming claudins (e.g. claudin-1, -3, -4, -8) (Krug et al., 2014). Depend-
ing on combination and proportion, they enable different barriers to have distinct func-
tion. For example, in the duodenum the overall expression of barrier-forming claudins 
is lower than in the colon, whereas the cation and water channel-forming protein, clau-
din-2, has an abundant expression in small intestine but only remote amounts in crypts 
of colon (Markov et al., 2010). This increase of tightening claudins from proximal to 
distal intestine fits to the diverse function of these intestinal segments that most of the 
ion and water transport takes place in the small intestine whereas the large intestine 
performs a fine tuning. Dysregulation of TJ proteins could cause or be caused by cor-
responding diseases due to altered paracellular passage of water, solute, and macro-
molecules (Krug et al., 2014). As an example, upregulation of claudin-2 under intestinal 
inflammatory conditions results in an increased diffusion of cations and water, leading 
to a so-called leak-flux diarrhoea (Sandle, 2005).  
1.2 Tricellular tight junction proteins 
At the region where three or more cells meet, the closely gathered bTJ strands elon-
gate towards the basal lamina in parallel instead of fusing together, which would con-
sequently leave an extra space in between of the vertical strands (Wade and 
Karnovsky, 1974). That is to say, the central tube, as an assumed weak spot, could 
serve as a potential route for transepithelial fluxes.  
As for molecular composition, there are two major components of tTJs, tricellulin com-
prising four transmembrane domains and the angulin family which passes the cell 
membrane only once (Masuda et al., 2011, Higashi et al., 2013) (Figure 3). Tricellulin 
is the first component found to have a predominant localization at tTJs (Ikenouchi et 
al., 2005). Six years later, a novel role of lipolysis-stimulated lipoprotein receptor (LSR) 
was identified as a tTJ protein (Masuda et al., 2011), followed by the discovery of its 
two homologous-gene-encoded proteins forming the angulin family and also mainly 




Figure 3 Molecular comparison of tTJ proteins. OCEL = occludin ELL-like 




Tricellulin, also known as MARVEL D2, is a tetraspan membrane protein with an N-
terminal and a C-terminal cytoplasmic region, first described in 2005 (Ikenouchi et al., 
2005). It localizes primarily at tTJs and has a ubiquitous expression in epithelial cells 
(Ikenouchi et al., 2005).  
Tricellulin is essential for maintaining an intact TJ structure as well as barrier function. 
Knockdown of tricellulin induces, on one hand, morphological reconstruction charac-
terizing by the disorganization of bTJs and tTJs, and on the other hand, functional 
change representing by a decrease of transepithelial resistance (TER) and an increase 
flux of 4 kDa fluorescein isothiocyanate-dextran (FITC-dextran, FD) (Ikenouchi et al., 
2005). Reversely, overexpression experiments indicated that tricellulin was responsi-
ble for regulating the passage of macromolecules (Krug et al., 2009b). When tricellulin 
was overexpressed only at tTJs, the permeability for small ions was unaltered, how-
ever, there was an extensive reduction of the permeability for macromolecules up to 
20 kDa. As a direct evidence, fluorescence live-cell imaging visualized the passage of 
macromolecules as 3 kDa dextran at tTJs (Krug et al., 2009b). 
Previous studies showed that bacteria and their products could disturb the paracellular 
barrier by targeting or regulating tricellulin (Nomura et al., 2014, Morampudi et al., 2016, 
Markov et al., 2019, Eum et al., 2014). Given the assumption that tTJs presumed to be 
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the break point of the overall TJ barrier, it is plausible to speculate that tricellulin acts 
a crucial part in preventing the crack of pathogens and immunogens. 
1.2.2 Angulins 
Angulins are the most recently identified protein family of TJs, composed of three pro-
teins known before as (i) LSR, (ii) immunoglobulin-like domain-containing receptor 1 
(ILDR1), and (iii) ILDR2 (Higashi et al., 2013). Angulins are defined as a protein family 
in consideration of their homology and localization at tTJs. Functionally, they share the 
capability of recruiting tricellulin to tTJs.  
Angulin-1 (also known as LSR) was initially recognized as a rate-limiting step in the 
progress of lipid clearance (Yen et al., 1994). Later, using a retrovirus-based cDNA 
screening, angulin-1 was identified to have a primary localization at tricellular contacts, 
which was then verified to be tTJs by immunofluorescence co-staining and immune-
freeze-fracture replica electron microscopy (Masuda et al., 2011).  
Angulin-1 could recruit tricellulin to tTJs, evidenced by a serial of experiments: 1) when 
tricellulin was knockdown, the localization of angulin-1 at tTJs was unaffected; 2) op-
positely, tricellulin was no longer concentrated at tTJs after extremely suppressing an-
gulin-1 expression; and 3) with re-expression of angulin-1, tricellulin regained its posi-
tion at tTJs (Masuda et al., 2011). Furthermore, this recruitment effect could not be 
reproduced with the absence of C-terminal cytoplasmic domain of tricellulin or the cy-
toplasmic region of angulin-1 (Masuda et al., 2011).  
As for barrier function, knockdown of angulin-1 led to an increased permeability to flu-
orescein and macromolecules up to 40 kDa and a decreased TER, which could be 
retrieved by its re-expression (Masuda et al., 2011, Higashi et al., 2013), indicating that 
angulin-1 was also essential for sustaining the epithelial barrier.  
Up to date, angulin-1 has been linked to lipid metabolic abnormality (El Hajj et al., 2019, 
Xie et al., 2018b, Akbar et al., 2016), Alzheimer’s disease (Xie et al., 2018a), and var-
ious cancers including gastric (Sugase et al., 2018), ovarian (Hiramatsu et al., 2018), 
endometrial (Shimada et al., 2017b, Shimada et al., 2017a, Shimada et al., 2016b), 
breast (Reaves et al., 2017, Reaves et al., 2014), and colon cancer (García et al., 
2007). For example, angulin-1 expression could serve as a potential prognostic bi-
omarker for colon cancer (García et al., 2007) and a decreased angulin-1 level was 
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related to enhanced cell invasion (Shimada et al., 2017b). Like tricellulin, bacteria also 
targeted angulin-1 in order to get through the apical barrier. Clostridium perfringens-
produced iota toxin could bind to N-terminal of angulin-1 and transport via endosomal 
trafficking leading to cytotoxicity (Nagahama et al., 2018). Clostridium difficile is an 
enteric pathogen which could cause serious diarrhoea. Clostridium difficile transferase 
(CDT) is a frequent toxin produced by hypervirulent strains and could target angulin-1 
as a host cell receptor by directly bounding to its extracellular immunoglobulin-like (Ig-
like) domain contributing to the invasion of host cells and the collapse of cytoskeleton 
(Hemmasi et al., 2015).  
Angulin-2 (also known as ILDR1) was first identified in 2004 with a 30 % homology to 
angulin-1 and a membranal localization of its two of three variants (Hauge et al., 2004). 
Apart from an large involvement in hearing loss (Borck et al., 2011, Diaz-Horta et al., 
2012, Nagtegaal et al., 2019), angulin-2 has been reported to be controversial in reg-
ulating paracellular water transport (Gong et al., 2017, Hempstock et al., 2020). Knock-
out of Ildr1 in mouse kidney resulted in an increased permeability to water causing 
renal concentrating defect and subsequently polyuria, while overexpression of Ildr1 in 
renal epithelial cells led to a decreased paracellular water permeability (Gong et al., 
2017). However, a more recent study where the localization of angulin-1 and -2 were 
also investigated showed that shifted localization of angulin-1 might have compen-
sated for the barrier function and therefore the overall water transport was not affected 
(Hempstock et al., 2020).  
Angulin-3 (also known as ILDR2) was related to type 2 diabetes at first (Dokmanovic-
Chouinard et al., 2008). Using single-cell RNA sequencing technique, the deficiency 
of angulin-3 gene was identified to be involved in the injury of cytoskeleton (Lu et al., 
2017). Angulin-3 was also presented an increased expression in inflamed inflammatory 
bowel disease patients’ tissues by immunohistochemistry (IHC) and a beneficial react 
in rheumatoid arthritis model by inhibiting T cell activation (Hecht et al., 2018). 
Regarding localization, angulin-1 and -2 are complementarily expressed in various ep-
ithelia in spite of a couple of overlap, whereas angulin-3 could be found mainly sur-
rounding neural tissues (Higashi et al., 2013). Furthermore, in each epithelium, there 
was at least one angulin localizing at tricellular contacts (Higashi et al., 2013). 
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As for the barrier function, both angulin-2 and -3 exhibited the ability to recruit tricellulin 
to the tTJ, yet their barrier functions are not identical to angulin-1 representing by dif-
ferent recovery levels of TER as well as permeability to flux tracers (Higashi et al., 
2013).  
1.3 Inflammatory bowel disease (IBD) 
Inflammatory bowel disease (IBD), consisting of ulcerative colitis (UC) and Crohn’s 
disease (CD), is a group of chronic idiopathic relapsing and remitting gastrointestinal 
conditions. Up to 21st century, although the incidence of IBD in western countries has 
stabilized, its prevalence remains climbing and has already exceeded 0.3 %; mean-
while in developing regions like Asia and South America on the other hand, an increas-
ing incidence of IBD has emerged (Ng et al., 2017, Kaplan and Ng, 2017).  
Although IBD could occur almost at any age, most patients get their diagnosis between 
30s and 40s, even five to ten years earlier for CD patients (Burisch and Munkholm, 
2015). As for mortality, patients with CD were reported to have a higher standardized 
mortality ratio (SMR)  of 1.14 to 1.52 than the general population (Canavan et al., 2007, 
Duricova et al., 2010, Manninen et al., 2012, Bewtra et al., 2013, Aniwan et al., 2018), 
whereas in UC the all-cause SMR showed no difference in comparison to the general 
population (0.71 to 1.17) (Jess et al., 2007, Manninen et al., 2012, Bewtra et al., 2013, 
Aniwan et al., 2018). Due to the lack of cure, the treatment for IBD aims at controlling 
to gain and remain remission and to prevent complications. Taken together, the devel-
oping prevalence, rather low mortality, early disease onset, and short of cure for IBD 
pose a heavy burden to every health system of the world.  
As the matter of aetiology, genetic predisposition, environmental factors, and intestinal 
microbiota are believed to contribute to the occurrence of IBD with the interaction of 
aberrant immune system (Figure 4). Until now, over 200 IBD-associated loci have 
been identified through Genome-wide association studies (GWAS). Studies in first-
degree relatives of IBD (Roth et al., 1989) and in twins of CD (Keita et al., 2018) sup-
ported the primary defect due to genetic predisposition. Environmental determinants 
involve factors in multiple aspects of life influencing the occurrence and development 
of the disease, such as smoking (Sutherland et al., 1990, To et al., 2016a, To et al., 
2016b), medicaments (Cornish et al., 2008, Moninuola et al., 2018, Zou et al., 2020), 
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and diet (Persson et al., 1992, Jantchou et al., 2010, Ananthakrishnan et al., 2013). 
Regarding the microbiome, numerous studies provided convincing evidence of the in-
volvement. Colonic bacteria were essential for inducing colitis in genetically suscepti-
ble mice (Veltkamp et al., 2001). Faecal transplantation has become an effective man-
agement of CD, and specific microbiota were reported to be an influencer of the course 
of IBD as well as a biomarker in therapy response prediction and the risk of recurrence 
(Ananthakrishnan et al., 2017, Yilmaz et al., 2019, Sokol et al., 2020). However, none 
of the factors seems to be indispensable and the exact mechanisms of pathogenesis 
of IBD still need to be explored.  
 
 
Figure 4 Risk factors of the pathogenesis of IBD. The occurrence of IBD is 
assumed to be the leverage of genetic, environmental, and microbial factors 
with complex interactions with the immune system miscommunicated with the 




Intestinal epithelial cells are constantly in the process of shedding and replenishing, 
proliferating, and differentiating, as well as absorbing necessary elements while pre-
venting unwanted entering.  As the source of nutrients, the gastrointestinal tract has to 
fulfil the function of digestion and absorption when facing a surfeit of antigens and toxic 
substrates within the lumen, which indubitably requires an intact and functional barrier 
to hold in between.  
The TJ is considered to be a critical component of the physical barrier. In IBD, the TJ 
changed in ultrastructure, expression, and localization. In active CD, freeze fracture 
analysis showed that TJ strands alone with the depth of its main meshwork were re-
duced, and the breaks or interruptions of the strands greatly were increased (Zeissig 
et al., 2007). At protein expression level, channel-forming claudin-2 was observed to 
be upregulated in both UC (Heller et al., 2005, Oshima et al., 2008) and CD (Zeissig 
et al., 2007). Claudin-4 and -7 were downregulated in UC (Oshima et al., 2008) while 
claudin-3, -5 and -8 in CD (Zeissig et al., 2007). The TAMP family member occludin 
was also found to be lower in both types of IBD (Zeissig et al., 2007, Heller et al., 2005) 
while tricellulin was found to be reduced in active UC (Krug et al., 2018). Regarding 
localization, in CD, claudin-5 was delocalized from the TJ to the lateral cell membrane 
(Zeissig et al., 2007) and tricellulin was shifted from depth of crypts to the surface 
epithelium (Krug et al., 2018). These changes of TJ fall into the impacts described 
above: (i) increased paracellular passage of water and solutes leading to classical leak 
flux diarrhoea and (ii) increased paracellular passage of macromolecules causing an 
enhancement of antigen uptake.  
However, whether the barrier dysfunction inclines to be the trigger or the consequence 
of IBD is difficult to define and using this monogenesis to explain seems also unrealistic. 
A recent hypothesis suggested a dysregulation between immune system and intestinal 
epithelial cells which on one hand reacted to microbiome and then communicated with 
immune system, and on the other hand adjusted epithelial barrier according to instruc-
tions from immune cells (Martini et al., 2017). Therefore, the molecular factors in be-





Figure 5 Clinical features of IBD. (a) Continuous inflammation in UC starting 
from the rectum (arrowhead, the most common affected segment) until far-
thest terminal ileum. (b) Segmental inflammation in CD with the possible 
emergence in the whole digestive tract. The arrowhead pointed the frequent 
region, the terminal ileum. (Neurath, 2019). 
 
1.3.1 Ulcerative colitis (UC) 
As one major type of IBD, ulcerative colitis (UC) was first reported in late 1800s, de-
scribing as idiopathic colitis with superficial ulcers of the colon and discharge of blood 
and mucus (Wilks and Moxon, 1889). This concept of UC up to now has developed to 
colonic inflammation that initiates from the rectum and continuously affects the proxi-
mal segments (Figure 5a). Based on the involved region in colon, UC could be classi-
fied as proctitis which is limited to rectum, left-sided colitis which compromises until 
splenic flexure, and extensive colitis which could affect the whole colon (Silverberg et 
al., 2005). The most common symptom is bloody diarrhoea, with more affected intes-
tinal duct, patients with UC may suffer from abdominal cramping and even constitu-
tional symptoms such as fever and fatigue.  
In spite of a slight preference of male (Murakami et al., 2019) or female (Selvaratnam 
et al., 2019) in the occurrence of UC reported, there is no significant gender difference 
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on the whole (Ungaro et al., 2017). Most of UC patients gets diagnosed at their 30s 
and a second peak was reported at 60s to 70s (Carroll et al., 2019, Jones et al., 2019, 
Mak et al., 2019, Ciapponi et al., 2020). The risk factors of the disease include familial 
predisposition (Moller et al., 2015), smoking (Ananthakrishnan, 2015), certain drug 
uses like current use of oral contraceptives (Wang et al., 2019) and hormone replace-
ment therapy (Khalili et al., 2012), while on the contrary appendectomy (Sahami et al., 
2016) and breastfeeding (Xu et al., 2017) seem to have a protective effect. 
The intestinal epithelial barrier is one of the targets of the inflammation and in theory 
also plays a role in initiating the disease. As the interface of the internal body and 
external environment, the intestinal epithelial barrier on one hand absorbs and digests 
variants nutrients and on the other hand prevents unwanted entering of antigens and 
toxic substrates within the intestinal lumen. In order to fulfil these functions, there is no 
doubt that the barrier has to be intact and fully functional. As described above, tTJ 
protein tricellulin is not only critical for the maintaining the overall TJ structure and bar-
rier function, but also plays a crucial role in the passage of macromolecules (Krug et 
al., 2009a).  
In active UC, tricellulin was shown to be downregulated and an impaired intestinal bar-
rier function exhibited as a decreased epithelial resistance along with an increased 
permeability for fluorescein and FD 4 kDa was observed in a recent study (Krug et al., 
2018).  
These findings raised the classical hen-or-egg question in the pathogenesis of UC: 
whether the downregulation of tricellulin is the reason of an increased luminal antigens 
uptake which succeedingly activates and supports the immune reaction or, the other 
way around, is only the consequence of the impaired barrier. To elucidate this relation 
between the downregulated tricellulin and the impaired barrier function might provide 
an insight to the pathophysiology of UC and potentially imply the upcoming relapse. 
Meanwhile, in CD, the other major type of IBD, a shift of the localization of tricellulin 
was demonstrated with an unchanged expression level of tricellulin (Krug et al., 2018), 
and angulin-1 which is responsible for the correct localization of tricellulin was down-
regulated in CD and could endamage the barrier function (Hu et al., 2020). In this con-
text, whether angulins are also involved in the relapse of UC needs to be investigated. 
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In UC, studies have also demonstrated the role of pro-inflammatory cytokines, espe-
cially produced by T helper (Th) 2 cells, during the pathogenesis of the disease. For 
example, lamina propria mononuclear cells (LPMCs) from UC patients release a sig-
nificant higher amount of pro-inflammatory cytokine interleukin-13 (IL-13) compared 
with controls, which could then alter TJs, represented by the upregulation of claudin-2 
that leads to a raise of solute and water passage and subsequently results in leak-flux 
diarrhoea (Heller et al., 2005). Latter research exhibited a decreased level of tTJ pro-
tein tricellulin and an increased passage of macromolecules, which could be induced 
by IL-13 through signaling pathways extracellular signal-regulated kinases (ERK) 1/2, 
c-Jun N-terminal kinases (JNK), and their common transcription factor activator protein 
1 (AP-1) (Krug et al., 2018).  
IL-13 is a cytokine discovered by a rich production of Th2 cells in inflammatory condi-
tions (Brown et al., 1989) and later it was revealed that innate immune cells such as 
eosinophils (Woerly et al., 2002), basophils (Smithgall et al., 2008), mast cells (Toru et 
al., 1998), natural killer (NK) cells and NK T cells (Fuss et al., 2004) were able to pro-
duce IL-13 as well. IL-13 is involved in a variety of mucosal inflammation, including UC 
(Heller et al., 2005), asthma (Huang et al., 1995), and several fibrotic disease like idi-
opathic pulmonary arterial hypertension (Daley et al., 2008) and systemic sclerosis 
(Hasegawa et al., 1997). Physiologically IL-13 is a supportive factor in antigen expul-
sion (Urban et al., 1998), but under pathological condition, the overwhelming of the 
cytokine becomes a damaging agent.  
There are two receptors for IL-13 that have been reported. The IL-13 receptor α1 (IL-
13Rα1) usually dimerizes with IL-4 receptor α (IL-4Rα), a receptor of IL-4 which is 
structurally resembling to IL-13, and signals mainly through signal transducer and ac-
tivator of transcription (STAT) 6. The type 2 receptor IL-13Rα2 on the contrary func-
tions as a monomer and has a higher affinity to IL-13 compared with type 1 receptor. 
Therapeutic biologicals regarding IL-13 include Pitrakinra, Anrukinzumab, and Traloki-
numab. Pitrakinra, instead of being an antibody, is in fact a mutated human recombi-
nant IL-4 protein that could prevent receptor complex formation between IL-4Rα and 
IL-13Rα1, which exerts negative effects on colitis (Palamides et al., 2016). Anrukin-
zumab, a monoclonal antibody that inhibits the binding between IL-13 and IL-4Rα, pre-
sents no improvement on active UC patients (Reinisch et al., 2015). Tralokinumab is a 
human IL-13-neutralizing IgG4 monoclonal antibody that has the capacity to block the 
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binding to both IL-13 receptors. The promising point was that clinical remission rate 
after Tralokinumab treatment increased from 6 % to 18 %, however, neither clinical 
response rate nor mucosal healing rate significantly improved (Danese et al., 2015). 
Inhibitory experiments of these two types of receptor in preceding research showed 
that IL-13 mediated claudin-2 upregulation through IL-13Rα1 while it downregulated 
tricellulin via IL-13Rα2 (Krug et al., 2018), which might explain the unsatisfactory re-
sults of the IL-13-related biologicals. 
1.3.2 Crohn’s disease (CD) 
Crohn’s disease (CD) is the other major type of IBD first reported as regional ileitis in 
1932 (Crohn et al., 1932). Unlike UC which affects principally only colon, CD can in-
volve the whole gastrointestinal tract, with terminal ileum being the most common af-
fected segment (Figure 5b). Clinical presentation of CD could differ in patients, de-
pending on involved location, severity of inflammation, and the presence and type of 
complications. Most frequent symptoms are right lower quadrant abdominal pain, 
chronic diarrhoea, and weight loss. CD has a higher incidence of extra-intestinal man-
ifestation and complications compared with UC. A cohort study reported a ratio of per-
forated or stenosed complication within three months after diagnosis being nearly one 
fifth and a cumulative risk of complication at 20 years after diagnosis being over 50 % 
(Thia et al., 2010). Perianal diseases could be seen in almost one third of CD patients, 
onset ranging from 18 years pre-diagnosis to 33 years post-diagnosis (Eglinton et al., 
2012). Endoscopically compared with UC, inflammation in CD is segmental instead of 
continuous, and lesions are rather transmural than superficial. According to disease 
location, CD could be classified as ileal, colonic, and ileocolonic disease, with isolated 
or combined upper gastrointestinal disease (Silverberg et al., 2005).  
A complicated interaction between genetic predisposition, environmental exposure, 
and intestinal microbiota could eventually give rise to CD by disordered immune re-
sponses and impaired epithelial barrier function. The expression and morphology 
changes of bTJs in CD has been described above. About tTJ proteins, tricellulin was 
left unchanged in CD compared with healthy controls. Nevertheless, its predominant 
localization seemed to have increased in the surface epithelium and extended from 
apical areas to more basolateral domains (Krug et al., 2018). Although the regulatory 
mechanisms behind this shifting and the underlying components are still unexplored, 
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a reasonable hypothesis would be that the displacement of tricellulin might result from 
elements responsible for its correct localization.  
1.3.3 Cytokines in CD 
Cytokines consist of hundreds of small molecular proteins involved in miscellaneous 
immunological regulations not only under pathological conditions like IBD, but also in 
healthy individuals. Cytokines play a vital role in balancing immune function, but when 
excessively produced they can also exert pathological effects on immune system. The 
involvement of cytokines in IBD could date back to 1980s when IL-2 was described to 
have a reduced level correlating to a diminished response of T cells to cell surface 
antigens (Ebert et al., 1984). GWAS identifying susceptible loci concerning IL-6, IL-12, 
IL-17, IL-21, IL-23, tumour necrosis factor (TNF)-α, interferon (IFN)-γ and so on spot-
lighted an indispensable character of cytokines in pathogenesis of IBD (Jostins et al., 
2012). Additionally, multiple genetically modified animal colitis models, such as IL-2-
deficient mice (Sadlack et al., 1993),  IL-7 transgenic mice (Samaridis et al., 1991), IL-
10-deficient mice (Kühn et al., 1993), supplemented the evidence of cytokines under-
standing in IBD. Regarding to the two subtypes of IBD, UC relates primarily to Th2-
related cytokines, while CD bounds closer to cytokines produced by Th1 and Th17 cells. 
This different profile of inflammatory cytokines between CD and UC may also explain 
their clinical heterogeneity and distinct pathological characteristics. 
As for the source of cytokines, there are numerous immune and non-immune cells 
possessing the capability to respond to various antigen stimuli and produce abundant 
pro- or anti-inflammatory cytokines, including epithelial cells, adipocytes, stromal cells, 
dendritic cells (DCs), macrophages, neutrophils, fibroblasts, innate lymphoid cell 
(ILCs), and a variety of T cells. These cells, along with their cytokine products, build a 
sophisticated interlaced network through every course of IBD (Figure 6). Disruption of 
the existing homeostasis possibly triggers the initiation of the inflammation which could 




Figure 6 Pro-inflammatory cytokine network in IBD. Cytokines from both in-
nate immunity and adaptive immunity (specifically Th1 and Th17 cytokines) 
are involved in Crohn’s disease. DC = dendritic cell, ILC = innate lymphoid 
cell, MAT = mesenteric adipose tissue, NK = natural killer cell. (For generation 




TNF-α has been deeply studied in IBD and the anti-TNF agent is the most classic 
biologic treatment for IBD. It is mostly produced by DCs, macrophages and differenti-
ated T cells. Once produced, TNF-α is also capable of activate macrophages to pro-
duce other pro-inflammatory cytokines in return. CD patients was reported to have an 
elevated TNF-α level (Sartor, 2006). Exposure to TNF-α resulted in a shifting of oc-
cludin and increased paracellular permeability to FD 4 kDa via apoptosis and cell shed-




1.3.3.2 The IL-1 family 
The IL-1 family is a cytokine family of 11 members largely involved in innate immunity, 
of which seven are pro-inflammatory cytokines including IL-1α, -1β, -18, -33, -36α, -
36β, and -36γ whereas four have anti-inflammatory properties (IL-1 receptor antago-
nist, IL-36Ra, IL-37 and IL-38). IL-1β plays a prominent role which does not have a 
general expression in healthy condition but could be rapidly induced through Toll-like 
receptor (TLR) signaling causing fever and immune activation (Piccioli and Rubartelli, 
2013). Mucosal IL-1Ra to IL-1 ratio was declined and IL-1β was augmented in CD 
promoting innate immune system, both of which were correlated to the disease activity 
(Reinecker et al., 1993, Casini-Raggi et al., 1995, Dosh et al., 2019). 
1.3.3.3 IL-6 
IL-6 is another proinflammatory cytokine produced by lamina propria macrophages and 
CD4+ T cells increasingly secreted in CD (Reinecker et al., 1993). After binding to its 
soluble receptor sIL-6R, the cytokine-receptor complex could bind to transmembrane 
protein gp130 and then activate antigen presenting cells (APCs) or T cells. A neutral-
izing protein to sIL-6R was able to ameliorate colitis activity and to induce apoptosis in 
adoptive transfer mice model, suggesting that one of the mechanisms of maintaining 
chronic inflammation in CD could be through prevention of T cell apoptosis (Atreya et 
al., 2000). 
1.3.3.4 The IL-12 family 
The IL-12 family consists of five members, IL-12, -23, -27, -35, and -39. IL-12 is a 
heterodimeric cytokine of p40 and p35 subunits, which could induce polarization of T 
cells and stimulate ILCs. It had a upregulated expression in LPMCs of CD compared 
with UC and controls (Monteleone et al., 1997). Resembling results were demonstrated 
with IL-23 which was a cytokine sharing the p40 subunit with IL-12 but also involved in 
Th17 pathway and suppressing the activity of regulatory T cell (TReg) (Liu et al., 2011). 
In T cell transfer model of colitis, IL-23 tended to be the initiating factor contributing to 
inflammation and motivated the production of IL-6 and IL-17 by memory CD4+ T cells 






Interferons, besides their antiviral function, play a part in immunomodulation by pro-
moting the activity of TReg and NK cells. In human, there are three types of interferons: 
type I contains the most members, IFN-α, -β, -ε, -ω, and -κ; type II and III are IFN-γ 
and IFN-λ respectively. IFN-γ is capable of catalysing major histocompatibility complex 
(MHC) on APCs and stimulating macrophages and lymphocytes to produce cytokines. 
In CD, lamina propria T lymphocytes secrete a remarkable amount of IFN-γ (Ghosh et 
al., 2006). It was reported that IFN-γ could lead to a decrease of transepithelial re-
sistance, an increase of paracellular permeability to FD 3 kDa, and additionally the 
localization of occludin, claudin-1 and claudin-4 were redistributed (Bruewer et al., 
2003). 
1.3.3.6 Th17 cytokines 
In addition to Th1 and Th2 cells, Th17 cells have also been identified as a latest T cell 
subset with the capability of IL-17A, IL-17F, IL-21, IL-22, and part of IFN-γ production. 
Th17 cells are the major source of IL-17 family which comprises of six members, IL-
17A to IL-17F. The prominent members of IL-17 are IL-17A and IL-17F that display 
50 % sequence similarity and that are expressed as homodimers or co-expressed as 
heterodimer (Wright et al., 2007). IL-17 was also found to be increased in CD (Sartor, 
2006). In dextran sulphate sodium (DSS)-induced colitis model, IL-17A knockout 
caused severer disease activity whereas IL-17F knockout moderated the symptoms 
(Yang  et al., 2008), which might explain the disappointed outcome of IL-17 antibody 
treatment in CD patients. 
IL-21, a cytokine belonging to the IL-2 family, is produced by Th17 cells and in recipro-
cal is also able to stimulate the differentiation of Th17 cells (Korn et al., 2007). IL-21-
induced phosphorylation of STAT 1 and STAT 3 is essential for the differentiation of 
human naïve B cells (Recher et al., 2011). In CD, IL-21 was shown to have an in-
creased expression regardless of subtypes of the disease when compared with UC 
and controls (Monteleone et al., 2005), which made IL-21 a potential target of new 
therapeutic strategy. Neutralizing IL-21 in adoptive transfer mice model showed an 




IL-22 comes from multiple sources in intestine, including ILCs, T cells, and NK cells, 
with a distinct expression in colon and small intestine (Mizoguchi, 2012). As a double 
agent in intestinal inflammation, on one hand, IL-22 promotes the production of mucus 
(Sugimoto et al., 2008), another character of intestinal barrier, stimulates regeneration 
of intestinal epithelial cells contributing to mucosal healing (Pickert et al., 2009); on the 
other hand, T cell-derived IL-22 was proven to be the pathogenesis of colitis in mice 
transfer model (Kamanaka et al., 2011). In active CD, IL-22 was found to have an 
elevated serum level (Zhang et al., 2017). 
1.3.3.7 Leptin 
Leptin is a special kind of cytokine secreted largely by white adipose tissue (WAT), 
therefore also classified as an adipokine. In terms of histology, there are two major 
types of adipose tissue, WAT and brown adipose tissue (BAT). BAT takes charge of 
thermoregulation whereas WAT is involved in energy storage as well as being a dy-
namic organ involved numerous physiological and metabolic processes. With exces-
sive nutrition, adipocytes grow hypertrophic and become hyperplasia, which leads to 
cell apoptosis, hypoxia, macrophages infiltration and pro-inflammatory cytokines re-
leasement (i.e. TNF-α, IL-1β and IL-6) (Trayhurn and Wood, 2004). Moreover, the WAT 
also possesses additional endocrine ability, secreting adipocytokines mainly leptin and 
adiponectin. 
The adipose tissue could also be categorised anatomically into subcutaneous adipose 
tissue (SAT) and visceral adipose tissue (VAT), the latter being of greater importance 
in CD. Mesenteric adipose tissue (MAT) is the peri-intestinal part of VAT, which under 
pathological condition could change its morphology. For example, in CD, a particular 
characteristic was described from the beginning termed as creeping fat – the thickened 
mesenteric fat tissue adjacent to inflamed intestinal segments (Crohn et al., 1952) – 
which could be an important source of additional adipokines. 
Leptin takes a part in both innate immunity by suppressing NK cells and activating 
monocytes, and adaptive immunity by promoting T cell proliferation and stimulating the 
production of cytokines (Abella et al., 2017). Under inflammatory condition, intestinal 
epithelial cells created an increasing amount of leptin which could then lead to the 
damage of epithelial wall and the infiltration of neutrophils (Sitaraman et al., 2004). 
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Interestingly, the existing data concerning serum leptin level in CD is highly incon-
sistent. Compared to controls, all possible regulatory directions have been reported, 
namely increased (Kahraman et al., 2017), unchanged (Frivolt et al., 2018, Valentini 
et al., 2009, Rodrigues et al., 2012), and decreased (Waluga et al., 2014, Karmiris et 
al., 2006). Nevertheless, the elevated tissue expression of leptin was quite identical 
between studies (Barbier et al., 2003, Paul et al., 2006). In mice in vivo experiment, 
administration of intrarectal leptin was able to induce inflammation after 48 h 
(Sitaraman et al., 2004). In vitro experiment in mouse liver and human endometrial cell 
lines, leptin showed the ability to downregulate angulin-1 at pathological dosage 
(Stenger et al., 2010, Shimada et al., 2016a). In addition, leptin has been linked to 
decreased TER and altered morphology of Zonula Occludens 1 (ZO-1), a typical rep-





IBD is a group of chronic relapsing and remitting gastrointestinal inflammations, whose 
exact pathogenesis remains to be elucidated. A recent hypothesis of miscommunica-
tion between intestinal epithelial cells and immune system enlightens the importance 
of recognition of molecular interactions in between to decrypt the disease. CD and UC 
are the two major types of IBD. 
TJs are critical in maintaining intestinal barrier function, the ultrastructure, expression, 
and localization of which are altered in IBD. The central tube formed by tTJs has been 
assumed to be a weak spot of the paracellular barrier. Tricellulin, one of the major 
components of tTJs essential for an intact TJ structure as well as the regulation of the 
passage of macromolecules, was shown to be downregulated in active UC and shifted 
in CD despite unchanged expression level. 
(1) The central aim of this work was to investigate the involvement of angulins in CD 
and to further unravel the regulating mechanisms behind. Angulins, as the other com-
ponents of tTJs, are responsible for the correct localization of tricellulin. Therefore, a 
more sophisticated alteration of tTJs involving the upstreaming regulator of tricellulin 
was hypothesized. For this purpose, the mRNA and protein expression of angulins 
were analysed using intestinal biopsies from CD patients and healthy controls. Further 
exploration of responsible cytokines, signaling pathways, and barrier function was per-
formed in human intestinal epithelial cell lines.  
(2) As a decrease of tricellulin expression enhanced macromolecule uptake in active 
UC, this part of the study was to explore the role of tricellulin downregulation during 
inflammation by analysing tricellulin expression levels, electrophysiological data, and 
flux changes in remission UC. 
(3) IL-13-mediated tricellulin downregulation was reported to signal via AP-1. Clarifica-
tion of the regulatory promotor elements involved was thus another aim of this thesis. 
Promoter activity analysis on wild type tricellulin promoter and mutations of potential 
binding sites (jun and fos) were performed.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Equipment 
7500 Fast Real-Time PCR System Thermo Fisher, Rockford, USA 
AccuBlock Digital Dry bath Labnet, Edison, USA 
Agarose gel electrophoresis chamber Corning, Kaiserslautern, Germany 
Biological safety cabinet HS 15 Heraeus, Hanau, Germany 
Centrifuge 
Qualitron DW-41, Artisan,  
Champaign, USA 
PerfectSpin 24R, Peqlab, Erlan-
gen, Germany 
Universal 320R, Hettich, Tut-
tlingen, Germany 
Confocal laser scanning microscope Carl Zeiss, Jena, Germany 
FastPrep-24 Classic Instrument MP Biomedicals, Illkirch, France 
Ice flaker Scotsman AF 80 Scotsman, Ipswich, UK 
Imaging system 
Fusion FX 7, Vilber Lourmat,  
Eberhardzell, Germany 
Azure, Biozym, Hessisch Olden-
dorf, Germany 
Incubator Binder CB 150 Binder, Tuttlingen, Germany 
Inverted microscope CK 2 Olympus, Tokyo, Japan 
Light source KL 1500 LCD Schott, Mainz, Germany 
Magnetic stirrers IKAMAG RCT IKA, Staufen, Germany 
Microplate Luminometer Centro LB 960 Berthold, Bad Wildbad, Germany 
Microplate reader Infinite M 200/Spectra clas-
sic 
Tecan, Switzerland 
Mini-PROTEAN® Tetra Vertical Electrophore-
sis Cell 
Bio-rad Laboratories, Feldkirchen, 
Germany 
Pipetboy acu 2 Integra, Biebertal, Germany 
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PowerPac power supply 
Bio-rad Laboratories, Feldkirchen, 
Germany 
Resistance measuring device 
Institut für Klinische Physiologie, 
CBF, Charité Berlin 
Rocking Platform WT 15 Biometra, Göttingen, Germany 
Secuflow fume cupboard Waldner, Wangen, Germany 
SevenCompact pH meter S 220 Mettler-Toledo, Singapore 
Thriller Thermoshaker incubator Peqlab, Erlangen, Germany 
Tissue Floatation Bath TFB 45 Medite, Burgdorf, Germany 
Ussing chamber 
Institut für Klinische Physiologie, 
CBF, Charité Berlin 
Vortexer RS-VA 10 Phoenix, Garbsen, Germany 
Water Purification System arium pro Sartorius, Göttingen, Germany 
 
3.1.2 Consumables 
10 ml serological pipet Corning, Kaiserslautern, Germany 
10 μL pipet tip Sarstedt, Nümbrecht, Germany 
100 μL pipet tip Sarstedt, Nümbrecht, Germany 
1000 μL pipet tip Sarstedt, Nümbrecht, Germany 
12-well plate Corning, Kaiserslautern, Germany 
15 ml polystyrene conical tube Corning, Kaiserslautern, Germany 
25 ml serological pipet Greiner Bio-One, Frickenhausen, 
Germany 
5 ml serological pipet Corning, Kaiserslautern, Germany 
50 ml polystyrene conical tube Corning, Kaiserslautern, Germany 
Cell culture flask (25 cm2) Corning, Kaiserslautern, Germany 
Cell culture flask (96 cm2) Corning, Kaiserslautern, Germany 
Cover glass VWR, Darmstadt, Germany 
Cryotubes Sarstedt, Nümbrecht, Germany 




Lysing matrix tube type D MP Biomedicals, Illkirch, France 
MicroAmp Fast Optical 96-Well Reaction Plate Thermo Fisher, Rockford, USA 
MicroAmp Optical Adhesive film Thermo Fisher, Rockford, USA 
Microscope slides R. Langenbrinck, Emmendingen, 
Germany 
Millicell-PCF insert (0.4 μm pore size) Merck Millicell, Darmstadt, Germany 
Millicell-PCF insert (3 μm pore size) Merck Millicell, Darmstadt, Germany 
Pipet (0.5 – 10 μL, 10 – 100 μL, 100 – 1000 μL) Eppendorf, Wesseling-Berzdorf, 
Germany 
PolyScreen PVDF transfer membrane Perkin Elmer, Rodgau, Germany 
Safe seal tube (1.5 mL) Sarstedt, Nümbrecht, Germany 
Single-cap PCR tube Biozym, Oldendorf, Germany 
Stirring rod (120 mm) Sarstedt, Nümbrecht, Germany 
Syringe Filter (25 mm, sterile) Th.Geyer, Renningen, Germany 
 
3.1.3 Chemicals 
50 x Tris-acetate/EDTA (TAE) buffer Serva, Heidelberg, Germany 
Acrylamide Carl Roth, Karlsruhe, Germany 
Agarose Basic Applichem, Darmstadt, Germany 
Albumin Thermo Fisher, Rockford, USA 
Alexa fluor antibody Molecular Probes MoBiTec,  
Göttingen, Germany 
Ammonium persulfate (APS) Sigma-Aldrich, Steinheim, Germany 
Ampicillin Ratiopharm, Ulm, Germany 
Bacto agar BD, MD, USA 
Bicinchoninic acid (BCA) protein assay reagent  
A + B 
ThermoFisher, Rockford, USA 
Bovine serum albumin (BSA) BIOMOL, Hamburg, Germany 
Bromphenol blue Sigma-Aldrich, Steinheim, Germany 




Dextran 4 kDa Serva, Heidelberg, Germany 
Dimethyl sulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
dNTPs NEB, Frankfurt am Main, Germany 
Dithiothreitol (DTT) Merck, Darmstadt, Germany 
Dual-Luciferase Reporter Assay System Promega, Walldorf, Germany 
Dulbecco’s PBS with Mg/Ca (PBS +/+) ThermoFisher, Rockford, USA 
Dulbecco’s PBS without Mg/Ca (PBS -/-) ThermoFisher, Rockford, USA 
Dulbecco's modified eagle medium (DMEM):  
F-12 Medium 
Sigma-Aldrich, Steinheim, Germany 
Ethanol (100 %) Merck KGaA, Darmstadt, Germany 
Ethanol (80 %) Th. Geyer, Renningen, Germany 
Ethidium Bromide (EtBr) Serva, Heidelberg, Germany 
Ethylene Diamine Tetra Acetic Acid (EDTA) Merck, Darmstadt, Germany 
Ethylene Glycol Tetra Acetic Acid (EGTA) Carl Roth, Karlsruhe, Germany 
Fetal bovine serum (FBS) ThermoFisher, Rockford, USA 
FITC-labelled Dextran 4 kDa TdB Labs, Uppsala, Sweden 
Fluorescein Sigma-Aldrich, Steinheim, Germany 
Glucose Carl Roth, Karlsruhe, Germany 
Glycerol Serva Electrophoresis, Heidelberg, 
Germany 
Glycine Carl Roth, Karlsruhe, Germany 
High Capacity cDNA Reverse Transcription kit Thermo Fisher, Rockford, USA 
Horseradish peroxidase (HRP) Sigma-Aldrich, Steinheim, Germany 
Hydrochloric acid (32 %) Carl Roth, Karlsruhe, Germany 
LB Medium Powder MP Biomedicals, Illkirch, France 
Lipofectamine 2000 Thermo Fisher, Rockford, USA 
Methanol Merck KGaA, Darmstadt, Germany 
Milk Powder Carl Roth, Karlsruhe, Germany 
Minimum Essential Medium (MEM) with glutamax Sigma-Aldrich, Steinheim, Germany 
Molecular weight marker (1 kb) Bioline, Luckenwalde, Germany 
Molecular weight marker (100 bp) Bioline, Luckenwalde, Germany 
NEB 10-beta Competent E. coli NEB, Frankfurt am Main, Germany 
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NEBuilder HiFi DNA assembly cloning kit NEB, Frankfurt am Main, Germany 
NucleoSpin Gel and PCR Clean-up Midi kit Macherey-Nagel, Düren, Germany 
NucleoSpin Plasmid Mini kit Macherey-Nagel, Düren, Germany 
NucleoSpin RNA/Protein kit Macherey-Nagel, Düren, Germany 
PageRuler  Thermo Fisher, Rockford, USA 
Paraformaldehyde (PFA, 16 %) EMS, PA, USA 
Passive lysis buffer Promega, Walldorf, Germany 
Polyvinylpyrrolidone (PVP, wt 40.000) Sigma-Aldrich, Steinheim, Germany 
Protease inhibitor cocktail tablets Roche, Mannheim, Germany 
QIAGEN Plasmid Midi Kit Qiagen, Hilden, Germany 
Quantablu™ Fluorogenic Peroxidase Substrate 
Kit 
Thermo Fisher, Rockford, USA 
Roswell Park Memorial Institute (RPMI) 1640 Me-
dium 
Sigma-Aldrich, Steinheim, Germany 
Sodium Dodecyl Sulfonate (SDS) Carl Roth, Karlsruhe, Germany 
Stable outgrowth medium NEB, Frankfurt am Main, Germany 
Super Signal™ West Pico PLUS Luminal  
Enhancer solution/Stable Peroxide Solution 
Thermo Fisher, Rockford, USA 
SuperSignal West Pico PLUS Chemiluminescent 
Substrate 
Thermo Fisher, Rockford, USA 
T4 DNA Ligase NEB, Frankfurt am Main, Germany 
TaqMan Universal PCR Master Mix Thermo Fisher, Rockford, USA 
Tetramethyl ethylenediamine (TEMED) Carl Roth, Karlsruhe, Germany 
Tissue glue B Braun, Melsungen, Germany 
Tric-HCl 0.5M, pH 6.8 Bio-rad Laboratories, Feldkirchen, 
Germany 
Tris Carl Roth, Karlsruhe, Germany 
Tris-HCl 1.5M, pH 8.8 Bio-rad Laboratories, Feldkirchen, 
Germany 
Triton X-100 Sigma-Aldrich, Steinheim, Germany 
Trypsin Sigma-Aldrich, Steinheim, Germany 
Tween 20 Acros Organics, Geel, Belgium 
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Water Millipore, MA, USA 
Xylol Carl Roth, Karlsruhe, Germany 
β-Mercaptoethanol Carl Roth, Karlsruhe, Germany 
 
3.1.4 Cell lines 
For cell culture experiments, the following three cell lines were used. 
3.1.4.1 HT-29/B6 cells 
HT-29 (ATCC® HTB-38™) is an intestinal epithelial cell line that originated from a col-
orectal adenocarcinoma of a 44-year-old Caucasian female in 1964 (Fogh and Trempe, 
1975). Its subclone HT-29/B6 was selected under glucose-free condition (Kreusel et 
al., 1991) and served as a model to explore the functions and mechanisms of intestinal 
epithelium. The basic properties of colonic epithelial cells are present in this cell clone 
as the cells possess a transepithelial resistance comparable to a tight colonic epithe-
lium, exhibit polarity and secret mucus. This cell line was used for the previous IL-13-
regulated tricellulin study (Krug et al., 2018), and therefore was also chosen for the 
follow-up experiments in this thesis, namely the transient transfection of tricellulin pro-
moter as well as cytokines treatment. 
3.1.4.2 T84 cells (ATCC® CCL-248™) 
The T84 cell line is also a human intestinal carcinoma cell line that originally derived 
from a site of lung metastasis of a 72-year-old male diagnosed with primary colon car-
cinoma and that afterwards transplanted in nude mice (Murakami and Masui, 1980). 
The expression of tight junction proteins and peptide hormones receptors made this 
cell line also suitable for mimicking epithelial barrier. T84 cells was used for cytokines 
treatments and electrophysiological measurements. 
3.1.4.3 Caco-2 cells (ATCC® HTB-37™) 
Caco-2 (Cancer coli-2) cells are another well-known epithelial cell line that was ob-
tained from a grade II colorectal adenocarcinoma of a 72-year-old Caucasian male 
(Fogh et al., 1977). They are characterized by the spontaneous property of differenti-
ation into a polarized adherent monolayer with a decreased colonocyte character and 
an increased enterocyte feature starting from 13 days after confluence (Engle et al., 
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1998). In this thesis, this cell line was used for cytokine treatments as well as electro-
physiological measurements. 
3.1.5 Buffers and solutions 
For Western Blot: 
Total lysis buffer 
Tris-Cl, pH 7.5 10 mM 
NaCl 150 mM 
Triton X-100 0.5 % 
SDS 0.1 % 
Protease inhibitor cocktail tablets 1 pill for every 10 mL before use 
 
Membrane lysis buffer 
1 M Tris-Cl, pH 7.4 2 mL 
1 M MgCl2 500 μL 
0.5 M EDTA 200 μL 
0.5 M EGTA 120 μL 
H2O add to 100 mL 
Protease inhibitor cocktail tablets 1 pill for every 10 mL before use 
 
5× Laemmli buffer 
SDS 2 g 
DTT 1.54 g 
0.5 M Tris, pH 6.8 5 mL 
Bromphenol blue 20 mg 
Glycerol 10 mL 
H2O add to 20 mL 




Separation gel (8.5 %) 
30 % Acrylamide 5.7 mL 
1.5 M Tris, pH 8.8 7 mL 
H2O 6.9 mL 
10 % SDS 200 μL 
10 % APS 200 μL 
TEMED 10 μL 
  
Separation gel (12.5 %) 
30 % Acrylamide 8.2 mL 
1.5 M Tris, pH 8.8 7 mL 
H2O 4.7 mL 
10 % SDS 200 μL 
10 % APS 200 μL 
TEMED 10 μL 
 
Premixed solution for stacking gel 
30 % Acrylamide 85 mL 
0.5 M Tris, pH 6.8 125 mL 
H2O 290 mL 
The solution needs to be kept in dark. 
 
Stacking gel 
Premixed solution for stacking gel 9.8 mL 
10 % SDS 100 μL 
10 % APS 100 μL 





10× West buffer 
Glycine 144 g 
Tris 30.4 g 
H2O add to 1 L 
 
Electrophoresis buffer for Western Blot 
10× West buffer 500 mL 
10 % SDS 50 mL 
H2O add to 5 L 
 
Transfer buffer 
10× West buffer 100 mL 
Methanol 100 mL 
H2O add to 1 L 
 
10× tris-buffered saline (TBS) 
NaCl 400 g 
Tris 60.5 g 
H2O add to 4.5 L 
The solution is first titrated to pH of 7.3 by HCl and then filled with H2O to 5 L. 
 
TBS/Tween 
10× TBS 500 mL 
Tween-20 5 mL 






BSA blocking solution 
BSA 5 g 
2.5 % Sodium azide 0.8 mL 
TBS/Tween add to 100 mL 
 
For Ussing chamber experiments: 
Ringer’s solution 
Solution I 225 g 
Solution II 525 g 
Solution III 25 mL 
H2O add to 5 L 
The solution needs to be gassed with Carbogen until clear. For cell culture experiments, 
0.1 g Glucose per 100 mL Ringer solution should be supplemented; for intestinal tis-
sues, 2.14 g Substrates mix needs to be added to 500 mL Ringer solution. 
 
20× Solution I for Ringer solution 
NaHCO3 35.28 g 
H2O add to 1 L 
 
10× Solution II for Ringer solution 
NaCl 66.4 g 
Na2HPO4 · 12 H2O 8.6 g 
NAH2PO4 · H2O 0.82 g 
KCl 4.05 g 
MgCl2 · 6 H2O 2.44 g 





50× Solution III for Ringer solution 
CaCl2 · 2 H2O 35.2 g 
H2O add to 1 L 
 
Substrates mix for Ringer’s solution 
Hydroxybutyrate 3.78 g 
L-Glutamine 21.924 g 
D-Mannose 108.12 g 
Glucose 118.8 g 
Imipenem 0.6 g 
Piperacillin 3.0 g 
 
For mutation construction: 
LB liquid medium 
LB Medium Powder 25 g 
H2O add to 1 L 
The solution needs to be autoclaved after preparation. 100 mg/mL Ampicillin need to 
be added before use. 
 
LB medium for agar plate 
Bacto agar 4.5 g 
LB liquid medium 300 mL 
The solution needs to be autoclaved after preparation. Before plating, it should be mi-
crowaved until solved and 100 mg/mL Ampicillin need to be added when the solution 





Electrophoresis buffer for agarose gel 
50× TAE 100 mL 
EtBr 250 μL 
H2O add to 5 L 
 
3.2 Methods 
3.2.1 Patients and study criteria 
IBD patients and patients without intestinal diseases visited at the endoscopy center 
of Department of Gastroenterology, Rheumatology and Infectious Diseases, Charité – 
Universitätsmedizin were enrolled to the study with prior consent. The diagnosis of IBD 
was based on the standard criteria (Gomollon et al., 2017, Ungaro et al., 2017) and 
the endoscopic activity was evaluated using endoscopy subscore of the Mayo score 
(Schroeder et al., 1987) or simple endoscopic score for CD (SES-CD) (Daperno et al., 
2004) for UC or CD respectively. 
Exclusion criteria were: age below 18 or above 80 years, pregnancy, presence of other 
major diseases (neoplastic diseases, other immunological diseases, and chronic in-
flammatory diseases), biotic treatment, presence of fistula or perforation, need of sur-
gery, lack of consent to the study.  
Healthy controls were free of gastrointestinal diseases (e.g., IBD, irritable bowel syn-
drome, diarrhoea, previous gastrointestinal surgery) and other major conditions de-
scribed above. The study was approved by the local ethics committee (No. 
EA4/015/13). 
For CD study, paraffin embedded tissues in stocking as well as fresh biopsies taken 
from sigmoid colon were used in the study. For UC study, biopsies were taken from 10 
cm, 30 cm, and 60 cm from anus. All samples were collected in disposable plastic 
containers filled with saline. The specimens for protein expression and mRNA analysis 
were stored in liquid nitrogen until analysis whereas those for Ussing chamber experi-
ments were carefully handled and glued as described in 3.2.4. 
39 
 
3.2.2 Cell culture 
All three human intestinal cell lines, HT-29/B6, T84, and Caco-2, were cultured at 37 °C 
in a 5 % CO2 in air atmosphere. For cultivating cells, 25 cm2 culture flasks were used 
and complete growth mediums for these three cell lines are listed as follow: 
 
Cell line Basic medium Supplements 
HT-29/B6 RPMI 1640 medium 
10 % FBS 
100 U/mL penicillin 
100 μg/mL streptomycin 
T84 DMEM: F-12 medium 
10 % FBS 
100 U/mL penicillin 
100 μg/mL streptomycin 
Caco-2 MEM with glutamax 
15 % FBS 
100 U/mL penicillin 
100 μg/mL streptomycin 
Medium was renewed every two to three days.  
3.2.2.1 Subculture of the cells 
In order to remove FBS traces which contain trypsin inhibitor in culture vessels, culture 
medium within flasks that needed to be passage was removed. Flasks were then rinsed 
with PBS -/- and pre-incubate with 3 mL of Trypsin-EDTA solution at 37 °C. After 5 min, 
the content was discarded and replaced with 1 mL of Trypsin-EDTA solution. The flask 
was then placed at 37 °C and when the cell layer was dispersed, 10 mL of complete 
growth medium were added to the flask. The cell suspension was aspirated by gently 
pipetting for five times.  
For new flasks, 1.5 mL of the cell suspension and 5.5 mL corresponding medium were 
added to culture vessels. For filters, cells were first counted using a cell counter and 4 
× 105 cells were seeded onto 3 μm (HT-29/B6 and T84 cells) or 0.4 μm (Caco-2 cells) 
pore-sized cell culture inserts. 
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3.2.2.2 Cytokines and inhibitors experiments 
To screen potential responsible cytokine(s), HT-29/B6, T84 and Caco-2 cells were in-
cubated with following cytokines for 24 h (TNFα) or 48 h (all the other cytokines).  
Cytokine Concentration Source 
TNFα 500 U/mL PeproTech, Hamburg, Germany 
IFNγ 1000 U/mL PeproTech, Hamburg, Germany 
Leptin 200 ng/mL PeproTech, Hamburg, Germany 
IL-1β 100 ng/mL PeproTech, Hamburg, Germany 
IL-6 10 ng/mL Miltenyi Biotec, Bergisch Gladbach, Germany 
IL-12 100 ng/mL PeproTech, Hamburg, Germany 
IL-13 100 ng/mL PeproTech, Hamburg, Germany 
IL-17A 100 ng/mL PeproTech, Hamburg, Germany 
IL-17F 100 ng/mL Miltenyi Biotec, Bergisch Gladbach, Germany 
IL-21 100 ng/mL Miltenyi Biotec, Bergisch Gladbach, Germany 
IL-22 50 ng/mL PeproTech, Hamburg, Germany 
IL-23 100 ng/mL PeproTech, Hamburg, Germany 
IL-33 100 ng/mL Miltenyi Biotec, Bergisch Gladbach, Germany 
Inhibitors were applied 1 h prior to leptin treatment at listed concentration. For the 96 
h of leptin treatment with or without inhibitors, the medium was renewed after 48 h 
along with the described concentration of leptin and corresponding inhibitors. 
Inhibitor Concentration Source 
U0126 10 μM 
Cell signaling Technology, Frankfurt am Main, Ger-
many 
LY294002 10 μM Calbiochem, Darmstadt, Germany 
AG490 100 μM Calbiochem, Darmstadt, Germany 
Stattic 20 μM Calbiochem, Darmstadt, Germany 





In order to measure the activity of tricellulin promoter activity, Lipofectamine 2000 was 
applied for transient transfection on HT-29/B6 cells with the constructs described 
above (WT, jun-mut, fos-mut, and DM tricellulin promoter) along with jun (NM_002228, 
OriGene, Herford, Germany), fos (NM_005252, OriGene, Herford, Germany). After 
growth in a 25 cm2 flask for eight days, HT-29/B6 cells was trypsinized and counted. 4 
× 105 cells were seeded onto Millicell-PCF inserts (pore size 3.0 μm, effective area 0.6 
cm2, Millipore, Bedford, MA, USA) in a 12-well plate and placed in a 5 % CO2 environ-
ment at 37 °C for 24 h. On the day of transfection, cells were washed with PBS -/- and 
800 μL of FBS-free RPMI 1640 medium was added. Following DNAs were diluted sep-
arately in 500 μL of RPMI 1640 medium along with additional 250 ng Renilla luciferase 
vector (pGL4.70, Promega, Walldorf, Germany) in each condition. 
DNA Amount (μg) 
Firefly luciferase vector (pGL4.10, Promega) 2.5 
Tricellulin WT promoter on pGL4.10 2.5 
Tricellulin jun-mut promoter on pGL4.10 2.5 
Tricellulin fos-mut promoter on pGL4.10 2.5 
Tricellulin DM promoter on pGL4.10 2.5 
Jun (SC118762, Origene, Herford, Germany) 1.25 
Fos (SC116873, Origene, Herford, Germany) 1.25 
 
Lipofectamine 2000 reagent was also diluted in 500 μL of RPMI 1640 medium in a 
DNA to Lipofectamine 2000 ratio of 4 to 1. Then, 500 μL of diluted Lipofectamine 2000 
were added to each diluted DNA and the mixture was incubated at room temperature 
for 15 min. Next, 210 μL of DNA-lipid complex were added to each filter and placed 
back to 5 % CO2 atmosphere at 37 °C. After 4 h, 100 μL of FBS with or without IL-13 
(200 ng/mL) were applied to each filter followed by a 48-hour incubation at 37 °C. 
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3.2.3 Molecular biological methods 
3.2.3.1 Protein extraction from formalin-fixed paraffin-embedded (FFPE) tissue 
To isolate protein from paraffin-embedded sections, Qproteome FFPE Tissue Kit (QI-
AGEN, Hilden, Germany) was used. FFPE Intestinal biopsies of CD patients were ac-
quired from sample stocks in the Institute for protein preparation. The protein extraction 
process was carried out according to the instruction the manual: 
Five sections with a thickness of around 15 μm of each tissue were cut and collected 
in one 1.5 mL collection tube. In a fume hood, 1 mL of xylene was pipetted into each 
tube followed by 10 s of vigorously vortexing, 10 min of incubation, 2 min of centrifu-
gation at top speed, and removal of the supernatant. The application of this step was 
then repeated twice. 1 mL of 100 % ethanol was pipetted into the same tube, which 
was subsequently mixed by vortexing, incubated for 10 min, and centrifuged for 2 min 
at top speed. After discarding the supernatant, this step was repeated once more. The 
same procedure was applied with 96 % and 70 % ethanol.  
To prepare a working solution of extraction buffer, 6 μL of β-mercaptoethanol were 
added to 94 μL of the EXB Plus buffer supplied by the kit. After pipetting 100 μL of the 
working solution, each tube was properly sealed using a collection tube sealing clip 
and incubated on ice for 5 min. In order to reverse formalin crosslinks, these tubes 
were heated to 100 °C for 20 min, and then agitated at 750 revolutions per minute (rpm) 
at 80 °C for 2 h to solubilize protein. Afterwards, the tubes were placed on ice for 1 min 
and the sealing clips were carefully removed. In the end, 15 min of centrifugation at 
14,000 × g at 4 °C was applied and the supernatant was transferred to a new 1.5 mL 
collection tube. 
3.2.3.2 Membrane protein extraction 
For harvesting membrane proteins from frozen intestinal biopsies, lysing matrix tubes 
containing ceramic beads were filled with 1.5 mL ice-cold membrane lysis buffer pre-
pared by 1 M pH 7.4 Tris-Cl, 1 M MgCl2, 0.5 M EDTA, 0.5 M EGTA and protease 
inhibitors. Each sample was put into one tube described above and was homogenized 
using a FastPrep-24 Classic Instrument (60 s, 4 m/s, MP Biomedicals, USA) for four 
times until no visible piece of the sample could be seen. After a primary centrifugation 
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(200 × g, 5 min, 4 °C), supernatants were transferred into new 1.5 mL tubes and again 
centrifuged at 42,100 × g for 30 min at 4 °C. Afterwards, pellets were resuspended in 
total lysis buffer (10 mM pH 7.5 Tris-Cl, 150 mM NaCl, 0.5 % Triton X-100, 0.1 % SDS 
and protease inhibitors) and stored at −80 °C. 
3.2.3.3 Total protein extraction 
To obtain total protein from cell culture samples, cells were washed with ice-cold  
PBS -/- and scraped from the Millicell-PCF inserts into a 1.5 mL tube after adding 200 
μL of ice-cold total lysis buffer, followed by an incubation on ice for 30 min with inter-
mittent vortex and a centrifugation at 15,000 × g for 15 min at 4 °C. The protein-con-
taining supernatants were stored at −80 °C. 
3.2.3.4 RNA and protein extraction (NucleoSpin RNA/Protein kit) 
To isolate both RNA and protein in parallel from the same sample, NucleoSpin 
RNA/Protein kit (Macherey-Nagel, Düren, Germany) was used to minimize the con-
sumption of precious biopsies.  
For homogenization of samples, each intestinal biopsy was put into lysing matrix tube 
containing 350 μL of RP1 buffer and 3.5 μL of β-mercaptoethanol and was then applied 
four time of the program described in 3.2.2.2 using FastPrep-24 Classic Instrument 
until no visible piece of sample could be observed. Next, the lysate was retrieved and 
pipetted onto a NucleoSpin Filter. After centrifugation at 11,000 × g for 1 min, 350 μL 
of 70 % ethanol was added to the flowthrough and the mixture was loaded to a Nucle-
oSpin RNA/protein column after properly mixing by pipetting up and down. A centrifu-
gation at 11,000 × g for 30 s at this step was applied to separate RNA which was then 
bound to the column membrane and protein which was soluble within the flowthrough.  
To purify RNA, 350 μL Membrane Desalting Buffer was added followed by a centrifu-
gation at 11,000 × g for 1 min. Meanwhile, rDNase reaction mixture was prepared by 
gently mixing 90 μL Reaction Buffer with 10 μL rDNase for each extraction, 95 μL of 
which was then pipetted onto the membrane and incubated at room temperature for 
15 min. To wash the membrane, 200 μL RA2 buffer and 600 μL RA3 buffer were ap-
plied followed by centrifuging at 11,000 × g for 30 s. An additional centrifugation at 
11,000 × g for 2 min was performed to dry the silica membrane. In the end, purified 
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RNA was harvested by applying 50 μL of RNase free H2O and centrifuging at 
11,000 × g for 1 min.  
As for protein, the flowthrough was transferred to a new 1.5 mL tube with the same 
volume of Protein Precipitator. After incubation for 10 min, the mixture was centrifuged 
for 15 min at top speed. To wash the protein, the supernatant was replaced by 500 μL 
of 50 % ethanol and centrifuged at 11,000 × g for 1 min. At last, extracted protein was 
obtained by discarding the supernatant and lysing in corresponding volume of total 
lysis buffer depending on the size of the pellet within the tube. 
3.2.3.5 Protein concentration measurement (BCA protein assay) 
The determination of protein concentration in this thesis is based on the colorimetric 
detection of Cu1+ reduced from Cu2+ by protein in an alkaline environment using BCA. 
For calibration, the concentration of 0.2 mg/mL, 0.8 mg/mL, and 1.2 mg/mL of BSA 
was prepared using a standard BSA solution of 2 mg/mL. The working solution of BCA 
assay was prepared by 50 parts of reagent A and 1 part of reagent B. 10 μL of BSA at 
above concentration along with H2O, corresponding lysis buffer, and each sample were 
then pipetted to a transparent 96-well plate, prior to adding 190 μL of the prepared 
BCA working solution. After incubation at 37 °C for 30 min, the absorbance of the plate 
was measured at 562 nm using a Tecan Spectra microplate reader. The protein con-
centration of unknown samples was calculated based on the linear relationship be-
tween BSA standard and its known concentration. 
3.2.3.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
PAGE is a typical protein electrophoresis method in use to analyse proteins. The pore 
structure of the polyacrylamide gel allows a size-selective (within the range of 5 to 250 
kDa) movement of protein in an electric field. SDS is introduced to the PAGE system 
to overcome its limitation of multi-subunit complexes formation and unpredictable 
movement, so that data interpretation of the gel based on the size of protein becomes 
feasible.  
Gels for SDS-PAGE are composed of separation gel and stacking gel. The separation 
gel is made from H2O, 30 % Acrylamide, Tris-HCl (pH 8.8), 10 % SDS, TEMED, and 
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APS. Depending on the size of the targeted protein, 8.5 % and 12.5 % gels were pre-
pared in this thesis. The gel was poured until around 3 cm distance left to the top of 
the glass chamber. 1 mL of 100 % ethanol were then gently distributed to the top of 
the gel to get rid of bubbles and to prevent the gel from drying out. After complete 
polymerization of the separation gel (approximately 20 to 30 min), ethanol was dis-
carded, and the remaining traces were absorbed using filter paper.  
The stacking gel contains 4 % of Acrylamide, and is mixed additionally with H2O, Tris-
HCl (pH 6.8), 10 % SDS, TEMED, and APS. After pouring the gel on top of the sepa-
ration gel, a comb was placed in to form the shape of wells. The whole gel was clamped 
into a vertical electrophoresis apparatus filled with electrophoresis buffer after fully pol-
ymerized. Prepared protein samples with 5× Laemmli buffer were heated to 95 °C for 
5 min and then loaded along with protein molecular mass marker. The electrophoresis 
was carried out at 100 V until the region of targeted size was well separated. 
3.2.3.7 Western blot 
For Western Blot, a wet transfer method using polyvinylidene fluoride membrane 
(PVDF) was performed. To start with the transfer, transfer buffer containing methanol, 
Tris and glycine was freshly prepared and pre-cooled at 4 °C. After SDS-PAGE, the 
gel was equilibrated in transfer buffer for 5 min, as well as the PVDF membrane which 
was activated in methanol until semi-transparent. Sponges were rinsed with transfer 
buffer to avoid air bubbles. To make a transfer sandwich, a gel holder cassette was 
first placed with the black side down in a container filled with enough transfer buffer to 
sink the whole sandwich. Then, a layer of sponge, a piece of filter paper, gel, PVDF 
membrane, a second piece of filter paper and sponge were carefully laid to within the 
cassette in this exact order while any air bubble was tried to avoid. Next, the sandwich 
was put into a transfer unit in the correct electrical direction. The wet transfer was taken 
place at 100 V for 60 min with an ice box inside the chamber and a magnetic stirrer 
constantly spinning. 
After transferring the protein from the gel to the membrane, the antibody binding pro-
cess starts. The blot was first blocked in blocking solution (1 % PVP-40 and 0.05 % 
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Tween-20) at room temperature for 1 h and then incubated overnight in the corre-
sponding primary antibody at 4 °C. Antibodies used in this thesis were diluted in 5 % 
BSA plus 0.02 % sodium azide in TBST and dilution ratios refer to the table below. 
Antibody Dilution ratio Source 
Rabbit anti-Tricellulin 1:2000 Abfinity, Invitrogen 
Rabbit anti-Angulin-1 1:3000 Sigma 
Mouse anti-β-actin 1:10000 Invitrogen 
Rabbit anti-Claudin-2 1:1000 Invitrogen 
Mouse anti-Claudin-4 1:1000 Invitrogen 
Rabbit anti-STAT3 1:1000 Cell signaling 
Rabbit anti-phosphorylated STAT3 1:1000 Cell signaling 
 
Next, the blot was washed 3 times for 10 min with TBST, followed by an incubation at 
room temperature for 1 h in the HRP-conjugated secondary antibody against corre-
sponding primary antibody. The secondary antibody was diluted to 1:10,000 in 1 % 
non-fat milk powder in TBST. After incubation, the blot was again washed 3 times for 
10 min with TBST. 
As for image detecting, SuperSignal West Pico Plus chemiluminescent substrate was 
prepared by one volume of Luminol/Enhancer solution and one volume of Stable Per-
oxide solution. The blot was rinsed in the mixed solution at room temperature for 2 min, 
quickly sealed within two transparent film foils, and immediately detected by Fusion 
FX7. In the end, densitometric analysis was performed using Multi Gauge V2.3 soft-
ware (FujiFilm, Japan). Intensities of the bands of the respective protein of interest 
were normalized using -actin as loading control. 
3.2.3.8 Polymerase chain reaction (PCR) 
PCR is one of the most common methods in molecular biology for rapidly amplifying 
DNA, which is achieved by three consecutive steps. Denaturation is the first step to 
start a PCR process. The double strands of DNA are separated by heating at certain 
temperature. The second step is annealing that primers bind to their complementary 
sequences on single DNA strand. In the end, the DNA polymerase comes into play for 
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extension from the end of the primer along the template DNA strand in the direction of 
5’ to 3’. 
As a critical role during PCR, different DNA polymerases possess diverse characteris-
tics leading to distinct amplifying behaviours from the prospect of thermostability, fidel-
ity and processivity. In order to construct mutants of tricellulin promoter, KAPA HiFi 
HotStart (Roche) polymerase was used in this reaction. For the five PCRs performed, 
following primers were used, respectively. In order to introduce mutations on wild type 
tricellulin promoter on luciferase vector (Figure 7), primers containing jun mutation 
were used in PCR jun-1, -2 and PCR jun-fos whereas primers with fos mutation in PCR 
fos-1, -2 and PCR jun-fos. 
 
Figure 7 Plasmid map and information (AP-1 binding site jun and fos, multiple 
cloning site NheI and HindIII, and PCR products used for mutation construc-




Forward primer jun-1 (Tm = 66.5 °C): 
5’-AGTGCAGGTGCCAGAACATTTCTCTGG-3’ 
Reverse primer jun-1 (Tm = 66.8 °C): 
5’-CCCCTAATGTCTTTCAAGATGATCCTGAGAG-3’ 
PCR jun-2: 
Forward primer jun-2 (Tm = 66.8 °C): 
5’-CTCTCAGGATCATCTTGAAAGACATTAGGGG-3’ 
Reverse primer jun-2 (Tm = 64.0 °C): 
5’-TGGCGCTGGGCCCTTCTTAATG-3’ 
PCR fos-1: 
Forward primer fos-1 (Tm = 66.5 °C): 
5’-AGTGCAGGTGCCAGAACATTTCTCTGG-3’ 
Reverse primer fos-1 (Tm = 68.0 °C): 
5’-CTGAGGCCATCTGAATATCGTAGGGCC-3’ 
PCR fos-2: 
Forward primer fos-2 (Tm = 63.2 °C): 
5’-GGCCCTACATGATTCAGATGGCCTCAG-3’ 
Reverse primer fos-2 (Tm = 64.0 °C): 
5’-TGGCGCTGGGCCCTTCTTAATG-3’ 
PCR jun-fos: 
Forward primer jun-fos (Tm = 66.8 °C): 
5’-CTCTCAGGATCATCTTGAAAGACATTAGGGG-3’ 




PCR reaction setup: 
Component Volume (µL) 
Nuclease-free H2O 16.5 
5× KAPA HiFi Fidelity Buffer 5 
10 mM dNTPs 0.75 
10 µM forward primer 0.75 
10 µM reverse primer 0.75 
Template DNA 0.75 
KAPA HiFi HotStart DNA Polymerase 0.5 
Total 25 
 
PCR thermocycling condition: 
Step Temperature (°C) Time 
Initial denaturation 95 3 min 
25 Cycles 
Denaturation 98 20 s 
Annealing 60 15 s 
Extension 72 4 min 
Final extension 72 5 min 
Hold 4 ∞ 
 
3.2.3.9 Agarose gel electrophoresis 
Agarose gel electrophoresis is a widely used method in molecular biology to separate 
DNA molecules according to the size. In an electric field, DNA moves towards the an-
ode due to its negative charge. The agarose gel during this process acts like a sieve 
because of its micropore structure. As a result, smaller DNA fragments travel faster 
than larger ones, and the compact form of plasmid DNAs also migrates more rapidly. 
Ethidium Bromide (EtBr) is a known carcinogen which could interact with DNA and 
fluoresce under ultraviolet (UV) light. Therefore, EtBr is a common dye added to the 
electrophoresis system to visualize the separated DNA.  
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For gel preparation, 1 % agarose gel was solved in 1× TAE buffer and microwaved 
until the solution appeared clear without floating particles. After cooling down to around 
50 °C, EtBr was added into the solution to a final concentration of 0.5 µg/mL. The 
solution was mixed by gently spun and then poured to an assembled electrophorese 
chamber inserted with a comb to form wells for samples. After polymerization, the gel 
was placed into a electrophoreses tank filled with 1× TAE buffer with 0.5 µg/mL EtBr, 
and the comb was carefully removed. Next, samples mixed with loading buffer were 
loaded into each well, along with the marker in the correct range of samples. The gel 
was run until the needed distance at 60 or 90 V depending on the size of the chamber. 
For detection, the gel was placed in an Azure instrument. Under UV light, the DNA was 
detectable, and size of samples were compared to the marker. 
3.2.3.10 Restriction enzyme digestion 
Restriction digestion is also a usual process in molecular biology used for digesting 
DNA strands by restriction enzyme to generate paired ends, so that afterwards two 
molecules of DNA are able to ligate together. Restriction enzymes are a group of en-
zymes that recognize and cut at a specific multiple cloning site of DNA. For firefly lu-
ciferase vector pGL4.10 (Promega, Walldorf, Germany) and tricellulin promoter, NheI-
HF (NEB, Frankfurt am Main, Germany) and HindIII-HF (NEB, Frankfurt am Main, Ger-
many) were introduced to the digestion system. 
Restriction enzyme digestion setup: 
Component Volume (µL) 
Nuclease-free H2O 15 
10× Cutsmart buffer (NEB) 2 
DNA (pGL4.10 or tricellulin promoter) 1 
Restriction enzyme NheI-HF 1 
Restriction enzyme HindIII-HF 1 
Total 20 
The reaction above was incubated at 37 °C for 1 h and inactivated by heating to 80 °C 




3.2.3.11 DNA extraction (from agarose gels) 
To extract DNA from an agarose gel, the band of interest was slice off under UV light, 
and the gel piece was collected in a 1.5 mL tube which was weighed with and without 
the gel. For each 100 µg of gel, 200 µL of NTI buffer from NucleoSpin Gel and PCR 
Clean-up Midi kit (Macherey-Nagel, Düren, Germany) was added into the reaction tube. 
Then, the sample was heated at 50 °C for around 10 min with intermittent vortex. After 
complete dissolution, the sample was loaded to a column provided by the kit and cen-
trifuged at 11,000 × g for 30 s. The silica membrane was washed with 700 µL NT3 
buffer, centrifuged at 11,000 × g for 30 s, and dried by another centrifugation step at 
11,000 × g for 2 min. In the end, the DNA sample was eluted with 20 µL of NE buffer 
by centrifuging 11,000 × g for 1 min. 
3.2.3.12 Ligation 
For constructing wild type (WT) tricellulin promoter on a firefly luciferase reporter vector 
pGL4.10, the digested (described in 3.2.2.14) and purified (as in 3.2.2.15) tricellulin 
promoter and pGL4.10 vector were connected together through their cohesive ends 
using T4 DNA Ligase (NEB, Frankfurt am Main, Germany).  
Ligation setup: 
Component Volume 
Tricellulin promoter 50 ng 
pGL4.10 vector 50 ng 
10× T4 DNA Ligase Buffer (NEB) 1 µL 
T4 DNA Ligase 1 µL 
Nuclease-free H2O add to 10 µL 
The reaction was incubated at 16 °C overnight and inactivated at 65 °C for 10 min. 
3.2.3.13 DNA assembly (NEBuilder HiFi DNA assembly cloning kit) 
Tricellulin promoter with jun-, fos-, and double-mutation in pGL4.10 vector were struc-
tured together using NEBuilder HiFi DNA assembly cloning kit (NEB, Frankfurt am 
Main, Germany) which was an emerging method for effectively assembling multiple 
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DNA fragments via an overlap of 15 to 80 base pair (bp). The assembly system works 
based on the synergistic effect of the exonuclease which generates a 3’ overhang, the 
polymerase which fills the vacancy digested by the exonuclease during annealing and 
the DNA ligase which seals the notch left. 
DNA assembly setup: 
Tricellulin jun-mutation promoter in pGL4.10: 
Component Volume (µL) 
2× NEBuilder HiFi DNA Assembly Master Mix (NEB) 4 
PCR jun-1 1 
PCR jun-2 2 
Digested pGL4.10 1 
Total 8 
 
Tricellulin fos-mutation promoter in pGL4.10: 
Component Volume (µL) 
2× NEBuilder HiFi DNA Assembly Master Mix (NEB) 4 
PCR fos-1 1 
PCR fos-2 2 
Digested pGL4.10 1 
Total 8 
 
Tricellulin double-mutation promoter in pGL4.10: 
Component Volume (µL) 
2× NEBuilder HiFi DNA Assembly Master Mix (NEB) 6 
PCR jun-1 1 
PCR fos-2 2 
PCR jun-fos 2 





Assembly thermocycling condition: 
Temperature (°C) Time 
37 15 min 




Transformation is a process of gene transfer, in detail the uptake of foreign DNA by 
bacteria. The eligible bacteria for transformation have the capability to take up extra-
cellular DNAs, therefore such bacteria are also termed as competent cells. In this the-
sis, NEB 10-beta Competent E. coli was utilized for the transformation of WT, jun mu-
tated, fos mutated and double mutated tricellulin promoter in pGL4.10 vector. 
Antibiotic selection acts like a first-line screen during cloning, which is carried out on 
account of the existence of an additional antibiotic gene in the vector used for trans-
formation. Therefore, when these specific antibiotics (i.e., ampicillin) are added during 
the preparation of culture plates, the growth of unwanted bacteria will be inhibited, as 
only positive clones contain the antibiotic resistance gene and are able to grow on the 
selection plate.  
The competent cells were first thawed on ice for 10 min. 5 µL of each DNA mentioned 
above was pipetted into the competent cells mix and gently mixed. After 30 min rest 
on ice, the mixture went through heat shock at 42 °C for 30 s and was placed on ice 
for 5 min. 950 µL of stable outgrowth medium (NEB) was added to the cell mixture 
which was then shook (250 rpm) at 37 °C. After 60 min, each mixture was spread onto 
a pre-warmed (37 °C) ampicillin selection plate (100 mg/mL) and incubated at 37 °C 
overnight. 
3.2.3.15 Plasmid isolation 
Plasmids are important extrachromosomal genetic source of bacteria, which allow the 
endowment of certain properties back to the bacteria. Therefore, plasmids provide 
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countless possibilities in recombinant DNA technology, and the isolation of plasmids 
paves the way to cloning, sequencing, transfection, etc. 
After transformation, when there were colonies grown on selection plates on the fol-
lowing day, several single colonies were picked with pipet tips and each was cultured 
in 2 mL Lysogeny broth (LB) liquid medium containing 100 mg/mL ampicillin at 37 °C 
overnight. The E. coli LB culture was used to harvest corresponding plasmid by Nucle-
oSpin Plasmid Mini kit (Macherey-Nagel). 
1.5 mL of the E. coli LB culture were added into a 1.5 mL tube which was centrifuged 
at 11,000 × g for 30 s. The pellet was then completely solved in 250 μL Buffer A1 by 
vigorously vortexing. 250 μL of Buffer A2 was the next added into the tube which was 
mixed by gently inverting 6 times and incubated at room temperature for 5 min until the 
solution turned clear. 300 μL of Buffer A3 was pipetted into the tube after incubation 
and again mixed by lightly inverting the tube for 6 times until the solution appeared 
colourless. Next, the tube was centrifuged at 11,000 × g for 10 min and the supernatant 
was loaded to a column provided by the kit. After centrifuging at 11,000 × g for 1 min, 
the column was washed with 500 μL Buffer AW and 600 μL Buffer A4 accompanied by 
a centrifugation at 11,000 × g for 1 min for each washing. The traces of ethanol were 
removed by additional centrifugation at 11,000 × g for 2 min. The plasmid DNA was 
eluted in 50 μL of Buffer AE after centrifuging at 11,000 × g for 1 min. 
The isolated plasmid DNAs were first checked by 1 % agarose gel and when confirmed 
by correct band size, the DNAs were further examined for jun and fos mutation by 
sequencing with following primers. 
Primer for jun sequencing: 
5’-GTGAAGTGGCTTATTTGAATCAAACCACCC-3’ 
Primer for fos sequencing: 
5’-ATTTCAATGGCCTAGCCAGTCTTCCTGTT-3’ 
When the results came back positive for corresponding mutation site, 500 μL of the E. 
coli LB culture matched to that sample was further cultivated in 50 mL LB liquid medium 
on a thermoshaker incubator at 225 rpm at 37 °C overnight. To isolate a larger volume 
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of plasmid DNAs, Qiagen plasmid Midiprep kit was applied with relatively similar ex-
traction steps to what described above in Miniprep. Afterwards, the plasmid DNAs were 
again verified by 1 % agarose gel and sequenced thoroughly using the primers below. 
Primer sequencing 1: 
5‘-CTAGCAAAATAGGCTGTCCC-3’ 
Primer sequencing 2: 
5‘-GTGAAGTGGCTTATTTGAATCAAACCACCC-3’ 
Primer sequencing 3: 
5‘-AACAGGAAGACTGGCTAGGCCATTGAAAT-3’ 
Primer sequencing 4: 
5‘-CATGCCATTCTCCTGCCTCA-3’ 
Primer sequencing 5: 
5‘-CAAGTAGAGTCATTTCCTCAAACATCTAAAT-3’ 
Primer sequencing 6: 
5‘-TGGCGCTGGGCCCTTCTTAATG-3’ 
3.2.3.16 Glycerol stocks 
For long-term storage, the bacterial cultures are preserved in medium with glycerol to 
be protected from ice crystal formation within the medium. 800 μL of the E. coli LB 
culture were mixed with 800 μL of sterile glycerol in a cryotube, which was then stored 
at −80°C. 
3.2.3.17 Promoter activity measurement 
Luciferase Reporter Assays are a common tool to study promoter activity. By applying 
two individual reporters within one single system, one as experimental and the other 
as internal control, could minimize the experimental variability, for example transfection 
efficiency, to a great degree. In the dual luciferase reporter (DLR) assay system, the 
firefly and Renilla luciferase are measured using one sample, which means, after a 
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stabilized luminescent signal from the firefly luciferase is generated and recorded, the 
firefly luminescence is quenched and a signal from the Renilla luciferase starts to ac-
cumulate. In this thesis, tricellulin promoter mutants were constructed on the firefly 
luciferase vector pGL4.10 while the Renilla luciferase vector pGL4.70 was co-trans-
fected as an internal control. 
At the end of 48 h of IL-13 treatment after transfection, the filters were rinsed with  
PBS -/-, and 250 μL of passive lysis buffer (Promega) were added onto the filters, from 
which the cells were next scraped off and collected in a 1.5 mL tube. The sample was 
then frozen by liquid nitrogen and thawed at 37°C twice, followed by centrifuging at top 
speed for 30s.  
For luciferase activity measurement, the supernatant was carefully taken into a new 
1.5 mL tube. 20 μL of obtained sample were pipetted onto a white 96-well plate and 
measured by a microplate luminometer Centro LB 960 (Berthold) after 10 s of incuba-
tion with 50 μL of luciferase assay reagent II (Promega) for firefly luciferase activity 
and subsequently 10 s incubating with 50 μL Stop & Glo (Promega) to acquire Renilla 
luciferase value. 
For additional protein expression analysis, 100 μL of total lysis buffer were added and 
mixed by pipetted up and down. Then, the same procedure was performed as de-
scribed in total protein extraction. 
3.2.3.18 RNA extraction from intestinal biopsies 
To obtain RNA, intestinal biopsies were collected and frozen using liquid nitrogen as 
soon as possible because of the instability of RNA. At the time of extraction, each 
sample was put in a lysing matrix tubes containing ceramic beads filling with 0.5 mL 
RNAzol (WAK-Chemie) and homogenized using a FastPrep-24 Classic Instrument (60 
s, 4 m/s, MP Biomedicals, USA) for four times until no visible piece of the sample could 
be seen. The solution was then transferred into a new Eppendorf tube followed by 
addition of 50 μL of chloroform. After 15 s of thoroughly vortex, the sample was incu-
bated at 4 °C for 5 min and centrifuged at 4 °C for 15 min at 12,000 × g. The aqueous 
phase was then carefully transferred into a new Eppendorf tube and mixed with same 
volume of isopropanol for RNA precipitation. After 30 min of incubation at 4 °C, the 
sample was again centrifuged at 4 °C for 15 min at 12,000 × g. Next, the supernatant 
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was discarded, and the RNA pellet was washed with 70 % ethanol. A centrifugation at 
4 °C for 10 min at 12,000 × g was then carried out and the supernatant was again 
discarded. The pellet was dried for around 5 min and then resuspended in 50 μL of 
nuclease-free water at 4 °C for 30 min. The sample was stored at −80 ° C. 
3.2.3.19 cDNA synthesis (High capacity cDNA reverse transcription kit) 
To synthesize cDNA from extracted RNA, a 2× Reverse Transcription Master Mix was 
first prepared on ice. For each reaction, the volume needed for each component is 
listed as follow: 
Component Volume (µL) 
Nuclease-free H2O 3.2 
10× RT Buffer 2.0 
10× RT Random Primers 2.0 
25× dNTP Mix 0.8 
RNase Inhibitor 1.0 
MultiScribe Reverse Transcriptase 1.0 
Total 10.0 
After pipetting 10 µL of the master mix to each single-cap PCR tube, 10 µL of RNA 
which was equilibrated to the same concentration were added into the tube. Air bub-
bles were then eliminated by briefly centrifugation. In the end, reaction tubes were 
placed to a pre-programmed thermal cycler (settings as below). 





Synthesized cDNAs were stored afterwards at −80 °C. 
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3.2.3.20 Real-time PCR (RT-PCR) 
RT-PCR is a method that allows the detection of the amount of cDNA reflected by the 
intensity of fluorescent signal. A comparative quantification could be carried out when 
a gene of interest is compared to a housekeeper gene (i.e., GAPDH) which is ex-
pressed uniformly in all measured samples.  
A master mix of PCR was prepared using the following setting: 
Component Volume per reaction (µL) 
2× TaqMan Universal PCR Master Mix 10 
20× gene of interest probe mix 1 
20x GAPDH probe mix 1 
Nuclease-free H2O 6 
 
18 µL of the master mix were then pipetted into a MicroAmp Fast Optical 96-Well Re-
action Plate, following by 2 µL of the cDNA sample (containing same concentrations) 
as well as nuclease-free H2O as negative control. The plate was sealed with a layer of 
MicroAmp Optical Adhesive film and briefly centrifuged to eliminate air bubbles and to 
collect contents to the bottom. Next, the plate was loaded in the RT-PCR instrument, 
and the listed program was pre-set and applied. 
Stage Temperature (°C) Time 
Hold 95 10 min 
40 Cycles 
95 15 s 
60 1 min 
 
To analyse the data, the difference cycle number between the gene of interest and 
GAPDH within one sample was first calculated as ΔCt. Each ΔCt value was then cal-
culated by subtracting the ΔCt value of a calibrator sample within the control group, 
expressed by ΔΔCt. The fold difference was interpreted therefore as 2−ΔΔCt. 
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3.2.3.21 Immunofluorescent staining 
For cell culture, cells growing on 0.4 µm-pore-size Millicell-PCF inserts were treated 
with corresponding cytokines and/or inhibitors as described in the part cytokines and 
inhibitors experiments. After the treatment, the cell monolayers were rinsed with  
PBS +/+, fixed with 2 % PFA in PBS +/+ at room temperature for 20 min, quenched with 
25 mM glycine in PBS +/+ at room temperature for 15 min to reduce autofluorescence, 
and permeabilized using 0.5 % Triton X-100 in PBS +/+ at room temperature for 7 min. 
Next, the cells were blocked with 5 % goat serum in PBS +/+ at room temperature for 
20 min, followed by an incubation with primary antibodies (listed in the table below) at 
4 °C overnight. 
Antibody Dilution ratio Source 
Rabbit anti-Tricellulin 1:1000 Invitrogen 
Rabbit anti-Angulin-1 1:1000 Sigma-Aldrich 
Mouse anti-ZO-1 1:200 Invitrogen 
 
On the following day, an incubation with secondary antibodies (Alexa Fluor 488 goat 
anti-mouse or Alexa Fluor 594 goat anti-rabbit, 1:500, Molecular Probes MoBiTec) and 
4’,6-diamidino-2-phenylindole (DAPI, 1:1000) was carried out at 37 °C for 1 h after two 
times washing with blocking solution. Then, the filter layer was shortly rinsed with H2O, 
cut off from the filter holder, and placed on the middle of an object slide. A single drop 
of mounting solution was dripped onto the filter layer which was in the end covered 
with coverslip. Confocal laser scanning microscope (LSM, Zeiss) were utilized for ob-
taining fluorescence images. 
3.2.4 Electrophysiological measurements 
3.2.4.1 Ussing chamber  
The Ussing chamber is a device invented more than half a century ago (Ussing and 
Zerahn, 1951) used for measuring transport properties as well as the barrier function 
of epithelium. The chamber is assembled by two hemi chambers which are continu-
ously gassed with carbogen to equilibrate O2 and CO2, and which are circulated with 
temperature-controlled water (Figure 8a). A polarized epithelial layer could be 
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mounted between the two hemi chambers with the modification of the sample container 
for cell culture (Kreusel et al., 1991) or intestinal biopsy (Stockmann et al., 1999) (Fig-
ure 8b, c).  
 
Figure 8 Schematic drawing of an Ussing chamber and the biopsy container. 
(a) Representative diagram of an Ussing chamber (Günzel et al., 2010). (b) 
Working scheme of a sample container for intestinal biopsies (Stockmann et 
al., 1999). 1 = mucosal side of the polyacrylic disk, 2 = support disk for gluing 
specimen, 3 = silicone rubber ring, 4 = serosal bipartite polyacrylic disk. (c) 
Sketch map of the biopsy container in detail according to DIN (Deutsches 
Institut für Normung) standards. The silicone ring has the same diameters as 
the support disk but is 0.19mm thick. All measures in the drawings are in 
millimetres (Stockmann et al., 1999). 
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3.2.4.2 Transepithelial resistance measurement 
The electrophysiological data like transepithelial resistance (TER) could be acquired 
by connecting the Ussing chamber to various apparatus, including a voltmeter, an am-
meter, a current source, an amplification device, and a computer. In order to eliminate 
the influence of the bath solution as well as the chamber compartments, the resistance 
of chamber filled with the same Ringer’s solution is measured before inserting the sam-
ple. This value will be subtracted in later calculation. 
In principle, the two electrodes at the outer edge provide a current applied on the epi-
thelial layer area, which generates a voltage change measured by the other two elec-
trodes close to the sample. The transepithelial resistance could be then calculated us-
ing Ohm’s law (R = U/I). 
3.2.4.3 Impedance measurement 
The transepithelial resistance measured as described above has a limitation due to the 
indiscrimination between different compartments of the sample, for example between 
epithelial resistance (Repi) and subepithelial resistance (Rsub), the sum of which is 
equivalent to the tissue resistance (Rt). This difference between Repi and Rsub does not 
always matter, however in IBD, the thickened subepithelial tissues increase the meas-
ured resistance value leading to an unchanged total transepithelial resistance in spite 
of a decreased resistance from the epithelial layer (Zeissig et al., 2004, Krug et al., 
2018), which could bring about inaccurate understanding of the barrier function under 
this circumstance. Therefore, the impedance measurement is introduced. 
Measuring the impedance relies on the resemblance between the cell membrane and 
a capacitor. The electric circuit of the sample is consisting of this capacitor and the 
epithelial resistance in parallel, which is then connected to the subepithelial resistance 
in series (Figure 9a) (Fromm et al., 1985, Günzel et al., 2010). The impedance is 
therefore measured at different alternating current (AC) frequencies (ω). At a very low 
frequency (ω → 0), the current would flow entirely through the epithelial resistor instead 
of the capacitor, which means the measured value represents the total resistance; at 
a very high frequency (ω → ∞), the epithelial resistor would be short circuited and 




Figure 9 Schematic diagram of impedance measurement. (a) Electric model 
of intestinal biopsies. (b) Nyquist diagram (plot of the real Zre and the imagi-
nary Zim portion of the impedance) for model shown in (a). (Krug et al., 2009c). 
 
3.2.4.4 Paracellular flux measurement 
Paracellular permeability properties could be reflected by tracers of different molecular 
size with the label of measurable substrate, such as fluorescein and FITC-labelled 
dextran. Adding equilibrium solution to both side of the chambers makes the measure-
ment of passive transport possible, since the osmotic and gradient difference are elim-
inated. 
For fluorescein measurement, the two hemi chambers were filled with 10 ml of Ringer’s 
solution after the sample was mounted in. After the resistance of the sample reached 
stable, 300 μL of basolateral solution was taken into a 1.5 mL tube as the blank sample 
and the hemi chamber was then filled with 300 μL of fresh Ringer’s solution. 10 μL of 
100mM fluorescein was pipetted apically and samples were taken at the time of 15 
min, 30 min, 45 min and 60 min, respectively. In order to determine the concentration, 
10 μL of the 100 mM fluorescein solution was diluted to 1 μM, 0.5 μM, 0.1 μM, 0.05 
μM, 0.01 μM, 0.005 μM and 0.001 μM for standard curve. 130 μL of each sample from 
Ussing chambers as well as from standard curve were measured at 520 nm by a spec-




𝐽 =  
(𝑐2 − 𝑐1) × 𝑉𝑐ℎ𝑎𝑚𝑏𝑒𝑟
(𝑡2 − 𝑡1) × 𝐴
 
J Flux 
c1, c2 Concentration of the time point 1 and 2 
Vchamber Volume of the added Ringer’s solution 
Vsample Volume of the sample 
t1, t2 Time of the sample taken 
 
Due to the concentration dependence of the flux, the value was then converted to per-






c Concentration of the substrate in Ussing chamber 
 
For FITC-dextran measurement, the procedure for determining the permeability was 
similar to that for fluorescein. The FITC-dextran was dialyzed before the experiment to 
avoid the disturbance by disjointed FITC fragments. For the experiment, the chambers 
were filled with 5 mL of Ringer’s solution. After the empty sample was taken, 25 μL of 
40 mM dextran was added to the basolateral side while 25 μL of 40 mM FITC-dextran 
to the apical chamber. The time points for FITC-dextran experiment were 0 min, 30 
min, 60 min, 90 min and 120 min. The measurement of the concentration as well as 
the calculation of the flux and the permeability were identical to what described for 
fluorescein above. 
3.3 Statistical analysis 
Data are expressed as mean values ± standard error of the mean (SEM). Statistical 
analyses were performed using Student’s t-test for comparison between two groups 
or one-way ANOVA in the occasion of more than two groups (multiple testing) and p 




4.1 Shifted localization of tricellulin in CD 
4.1.1 Patients features 
From 2017 to 2020, 19 CD patients as well as 24 control patients described as in 3.2.1 
were recruited to the study and underwent colonoscopy (Table 1). The disease activity 
was evaluated based on the clinical manifestation and simple endoscopic score for CD 
(SES-CD). SES-CD is a commonly used scoring system for assessing endoscopic ac-
tivity of CD, including the following aspects: mucosal ulcers, surface involved by CD or 
ulceration, and the presence of narrowing (Daperno et al., 2004).  
Table 1 Characteristics of the enrolled CD population. 
Characteristic Control (n = 24) CD (n = 19) 
Age (median, range) 54 (24-66) 35 (25-64) 
Gender (male/female) 8/16 5/14 
SES-CD, n   
Remission (0-2) - 5 
Active (> 2) - 14 
 
4.1.2 Expression of angulins in intestinal biopsies 
To investigate the expression of angulins, intestinal biopsies were collected from the 
enrolled patients with prior consent. First, on mRNA level, angulin-1 was downregu-
lated in active CD (CDActive) compared with controls (Ctrl) and remission patients 
(CDRem) (Figure 10a, *p < 0.05). The expression of angulin-2 demonstrated a resem-
bling pattern but statistically unsignificant (Figure 10b). Angulin-3 was within the simi-
lar range in CD as in Ctrl (Figure 10c).  
In order to be comparable with previous studies (Zeissig et al., 2007, Krug et al., 2018), 
the mRNA expression of TJ proteins tricellulin, claudin-2 (Cldn-2) and claudin-4 (Cldn-
4) were also analysed. Tricellulin did not change in CD compared with Ctrl (Figure 
10d). Cldn-2 showed an upregulation in CDActive in comparison with Ctrl (Figure 10e, 
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**p < 0.01) and CDRem (Figure 10e, *p < 0.05). Cldn-4 was unaltered in CD and in Ctrl 







Figure 10 Scatterplot with bar of mRNA expression of TJ proteins in human 
intestinal tissues. Mean value of Ctrl is set to 100 %. (a) Angulin-1 was down-
regulated in active CD (28.26 ± 7.62 %, n = 11) compared to Ctrl (100 ± 
16.81 %, n = 22, *p < 0.05) and remission patients (116.86 ± 27.87 %, n = 5, 
*p < 0.05). (b) Angulin-2: Ctrl = 100 ± 21.85 %, n = 24; CDActive = 37.63 ± 
16.14 %, n = 11; CDRem = 97.44 ± 12.52 %, n = 5). (c) Angulin-3: Ctrl = 100 ± 
27.54 %, n = 20; CDActive = 87.76 ± 46.96 %, n = 8; CDRem = 133.09 ± 44.91 %, 
n = 5. (d) Tricellulin: Ctrl = 100 ± 16.75 %, n = 22; CDActive = 67.87 ± 28.82 %, 
n = 11; CDRem = 114.90 ± 25.69 %, n = 5. (e) Cldn-2 showed an increasement 
in CDActive (256.28 ± 48.51 %, n = 7) in comparison with Ctrl (100 ± 18.61 %, 
n = 19, **p < 0.01) and remission CD (76.67 ± 30.36 %, n = 4, *p < 0.05). (f) 
Cldn-4: Ctrl = 100 ± 28.64 %, n = 20; CDActive = 127.67 ± 39.31 %, n = 11; 
CDRem = 68.33 ± 29.68 %, n = 5. 
 
Next, the protein expression of angulin-1 was analysed using intestinal biopsies in 
FFPE sections and showed a downregulation in CD compared to Ctrl (Figure 11a, b, 
*p < 0.05). Due to the potential heterogeneous distribution of epithelial cells within 
FFPE sections, intestinal biopsies which were directly frozen in liquid nitrogen and did 
not underwent fixation or embedding were then investigated for the avoidance of sam-
ple selection bias. Angulin-1 protein expression was also downregulated in CDActive and 
recovered in CDRem (Figure 11c, d, **p < 0.01), similar to the findings at mRNA level. 
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As controls, the protein expression of tricellulin and Cldn-4 were also analysed and 








Figure 11 Analysis of TJ protein expression in human intestinal tissues. Mean 
value of Ctrl is set to 100 %. (a) Scatterplot with bar of Angulin-1 in FFPE 
section of Ctrl and CD. Angulin-1 was downregulated in CD (Ctrl: 100 ± 
19.42 %, n = 6; CD: 55.82 ± 3.67 %, n = 6, *p < 0.05). (b) Representative 
western blots of FFPE sections from Ctrl and CD. (c) Scatterplot with bar of 
Angulin-1 in biopsies directly frozen after colonoscopy from Ctrl, CDActive, and 
CDRem. Angulin-1 was downregulated in CDActive (49.43 ± 11.13 %, n = 13) 
compared with Ctrl (Ctrl: 100 ± 11.34 %, n = 15, **p < 0.01) and CDRem 
(131.00 ± 12.21 %, n = 5, **p < 0.01). (d) Representative western blots of 
fresh intestinal biopsies from Ctrl, CDActive, and CDRem. (e) Scatterplot with bar 
of tricellulin in biopsies directly frozen after colonoscopy from Ctrl, CDActive, 
and CDRem. Ctrl: 100 ± 7.64 %, n = 15; CDActive: 107.60 ± 9.70 %, n = 13; 
CDRem: 86.31 ± 6.93 %, n = 5. (f) Representative western blots of tricellulin. 
(g) Scatterplot with bar of Cldn-4 in biopsies directly frozen after colonoscopy 
from Ctrl, CDActive, and CDRem. Ctrl: 100 ± 9.24 %, n = 15; CDActive: 85.23 ± 
10.80 %, n = 13; CDRem: 101.98 ± 7.41 %, n = 5. (h) Representative western 
blots of Cldn-4. 
 
4.1.3 Cytokine effects of angulins in human intestinal epithelial cell lines 
To explore the underlying mechanisms of angulin-1 downregulation in CD, twelve pro-
inflammatory cytokines (TNF-α, IFN-γ, Leptin, IL-1β, IL-6, IL-12, IL-17A, IL-17F, IL-21, 
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IL-22, IL-23 and IL-33) that were commonly involved in the disease were applied to 
three human intestinal epithelial cell lines (T84 and Caco-2, HT-29/B6). 
In T84 cells, angulin-1 was only downregulated by leptin (Figure 12c, ***p < 0.001), 
while none of the other cytokines had an effect on angulin-1 protein expression level 
(Figure 12). Tricellulin was increased by IL-6 (Figure 12e, *p < 0.05) and decreased 
by IL-22 (Figure 12j, ***p < 0.001). The upregulation of Cldn-2, which was a typical TJ 
change in CD (Zeissig et al., 2007), was able to be induced with the treatment of TNF-
α, IL-6, IL-12, IL-17A, and IL-22 (Figure 12a, e, f, g, j, ***p < 0.001). On the contrary, 
the reduction of Cldn-2 could be caused by IFN-γ, IL-17F and IL-33 (Figure 12b, h, l, 
***p < 0.001). Cldn-4 was elevated after incubation with (Figure 12e, **p < 0.01), IL-
12 (Figure 12f, ***p < 0.001), IL-17A (Figure 12g, *p < 0.05), or IL-22 (Figure 12j, **p 
< 0.01). As for TER, leptin showed no effect after treatment (Figure 13c). A reduced 
TER was observed when T84 cells were treated with TNF-α, IL-6 or IL-22 (Figure 13a, 












Figure 12 Cytokines effect on TJ protein expression in T84 cells. Densitomet-
ric analysis revealed that leptin led to a downregulation of angulin-1 to 81.11 
± 2.07 % of untreated Ctrl after 48 h (c, ***p < 0.001, n = 12), while other 
cytokines did not affect angulin-1 expression. Tricellulin expression was re-
duced by 48 h of IL-22 treatment (j, ***p < 0.001, n = 12) while elevated by 










Figure 13 Cytokines effect on TER in T84 cells. 24 h of TNF-α treatment, 48 
h of IL-6 or IL-22 reduced the TER to 69.37 ± 1.93 % (a, ***p < 0.001, n = 9), 
71.12 ± 3.45 % (e, ***p < 0.001, n = 9), and 50.42 ± 2.22 % (j, ***p < 0.001, 
n = 9) respectively. 
 
In Caco-2 cells, leptin was also the only cytokine that led to a downregulation of angu-
lin-1 (Figure 14c, ***p < 0.001). A slight increase of angulin-1 was observed after the 
treatment with TNF-α (Figure 14a, **p < 0.01) or IL-17F (Figure14h, *p < 0.05). All the 
cytokines tested resulted in non-significant change of tricellulin protein expression 
(Figure 14). Cldn-2 was upregulated by TNF-α (Figure 14a, ***p < 0.001), IL-6 (Figure 
14e, ***p < 0.001), IL-17F (Figure 14h, *p < 0.05), IL-22 (Figure 14j, ***p < 0.001), 
and IL-33 (Figure 14i, *p < 0.05), whereas Cldn-4 protein expression was increased 
by TNF-α (Figure 14a, ***p < 0.001), IL-6 (Figure14e, *p < 0.05), IL-17F (Figure14h, 
*p < 0.05), and IL-22 (Figure14j, *p < 0.05). As for TER, there was also no significant 
change observed after leptin treatment (Figure 15c), while TNF-α (Figure 15a, ***p < 














Figure 14 Cytokines effect on TJ protein expression in Caco-2 cells. After 48 
h treatment of leptin, angulin-1 was downregulated to 82.38 ± 1.03 % (c, ***p 
< 0.001, n = 12). On the contrary, TNF-α and IL-17F could slightly upregulate 








Figure 15 Cytokines effect on TER in Caco-2 cells. The TER of Caco-2 cells 
was decreased after 24 h of TNF-α treatment (a, ***p < 0.001, n = 9) as well 
as 48 h treated with IL-22 (j, **p = 0.001, n = 9). 
 
In HT-29/B6 cells, unlike T84 or Caco-2 cells, angulin-1 protein expression was not 
affected by 48 h of leptin treatment (Figure 16c) but was slightly increased by IL-33 
(Figure 16l, ***p < 0.001). Like T84 cells, a decreased tricellulin protein level was ex-
hibited after IL-22 treatment (Figure 16j, **p < 0.01); in addition to IL-6 (Figure 16e, 
**p < 0.01), tricellulin could also be upregulated by IL-21 (Figure 16i, **p < 0.01). Cldn-
2 was raised due to TNF-α (Figure 16a, ***p < 0.001), IL-17A (Figure 16g, ***p < 
0.001), IL-21 (Figure 16i, ***p < 0.001), IL-22 (Figure 16j, ***p < 0.001), and IL-23 
treatment (Figure 16k, *p < 0.05), whereas decreased by IFN-γ and IL-33 (Figure 16b 
and l, ***p < 0.001). TNF-α, IFN-γ and IL-22 decreased TER in HT-29/B6 cells (Figure 













Figure 16 Cytokines effect on TJ protein expression in HT-29/B6. Angulin-1 
was upregulated to 125.38 ± 3.97 % of untreated Ctrl after 48 h IL-33 treat-
ment (l, ***p < 0.001, n = 9). Tricellulin was decreased by IL-22 to 69.98 ± 
5.28 % (j, **p < 0.01, n = 9) but increased by IL-6 to 120.84 ± 3.32 % (e, **p 








Figure 17 Cytokines effect on TER in HT-29/B6. TER was reduced to 42.66 
± 2.30 % by TNF-α (a, ***p < 0.001, n = 9), 59.31 ± 4.03 % by IFN-γ (b, ***p 
< 0.001, n = 9), and 51.88 ± 2.22 % by IL-22 (j, ***p < 0.001, n = 9). 
 
 
Then, leptin treatment for different time periods (24 h, 48 h and 96 h) was applied and 
the protein expression of angulin-1 and tricellulin was investigated. In T84 cells, angu-
lin-1 only showed a tendency of decrease after 24 h of treatment (Figure 18a, n = 6) 
whereas 96 h of leptin treatment led to nearly 50 % of angulin-1 downregulation (Fig-
ure 18a, ***p < 0.001, n = 12). The protein expression of tricellulin was comparable at 




Figure 18 Protein expression effect of leptin at different time point in T84 cells. 
(a) Densitometric analysis showed angulin-1 expression to be 90.68 ± 3.83 % 
at 24 h (n = 6), 81.11 ± 2.07 % at 48 h (***p < 0.001, n = 12), and 58.66 ± 
2.62 % at 96 h (***p < 0.001, n = 12) compared to untreated Ctrl. The protein 
expression at 96 h was decreased compared to both 24 h (***p < 0.001) and 
48 h (***p < 0.001). At 48 h, angulin-1 expression was also lower than 24 h 
(*p < 0.05). (b) Tricellulin expression level had no difference between 24 h (n 
= 6), 48 h (n = 12), and 96 h (n = 6). 
 
In Caco-2 cells, angulin-1 protein expression demonstrated a similar time-dependent 
pattern and was downregulated to a larger extent after 96 h of leptin treatment com-
pared to untreated Ctrl (Figure 19a, ***p < 0.001, n = 12) as well as treatment for 24 h 
(Figure 19a, ***p < 0.001, n = 6) or 48 h (Figure 19a, ***p < 0.001, n = 12). Likewise, 





Figure 19 Protein expression effect of leptin at different time point in Caco-2 
cells. (a) Angulin-1 expression level exhibited reduction at 48 h (82.38 ± 
1.03 %, ***p < 0.001, n = 12) and 96 h (67.71 ± 1.68 %, ***p < 0.001, n = 12) 
of leptin treatment compared to untreated Ctrl. There was significant differ-
ence between 24 h and 48 h (***p < 0.001), 48 h (***p < 0.001) and 96 h (***p 
< 0.001), and 24 h and 96h. (b) Tricellulin expression was not affected by 
leptin at 24 h, 48 h, nor 96 h. 
 
4.1.4 Barrier function of T84 and Caco-2 cells treated with leptin 
To determine whether this expressional change of angulin-1 could lead to alteration of 
macromolecule passage, TER as well as permeability for the macromolecule marker 
FITC-dextran 4 kDa (FD4) was investigated in T84 and Caco-2 cells treated with leptin. 
In both cell lines, the TER values remained at a similar level after incubation with leptin 
compared with Ctrl (Figure 20a, c). As for the permeability for FD4, the results between 
Ctrl and leptin group were comparable in T84 cells (Figure 20b), whereas in Caco-2 




Figure 20 Functional analysis in T84 and Caco-2 cells. (a) Transepithelial 
resistance in T84 cells. (b) Permeability for FITC-dextran 4 kDa in T84 cells: 
Ctrl = 0.075 ± 0.005 · 10-6 cm · s-1, n = 9; Leptin = 0.086 ± 0.01 · 10-6 cm · s-1, 
n = 8. (c) Transepithelial resistance in T84 cells. (d) Permeability for FITC-
dextran 4 kDa in Caco-2 cells: Ctrl = 0.045 ± 0.008 · 10-6 cm · s-1, n = 9; Leptin 
= 0.083 ± 0.016 · 10-6 cm · s-1, n = 11, *p < 0.05. 
4.1.5 Tricellulin localization after leptin treatment 
Immunofluorescent staining was then carrier out in order to investigate whether a 
shifted localization of tricellulin could also be induced by leptin treatment. The localiza-
tion of tricellulin was not changed and remained at tTJs in both T84 and Caco-2 cells 




Figure 21 Representative immunofluorescent staining of tricellulin (green) 
and ZO-1 (red) in human intestinal cell lines. Nuclei were stained using DAPI 
(blue). With the TJ indicator ZO-1, the localization of tricellulin at tTJs are 
demonstrated. The selected Z-scans (yellow box) are magnified on the right, 
indicating that there were no localization shifts in lateral direction. Bars = 10 
μm. 
 
4.1.6 Signaling pathway of leptin 
Regarding the signaling pathways of leptin, JAK2 (Myers et al., 2008), STAT3 
(Shimada et al., 2016a), ERK1/2 (Banks et al., 2000), and PI3K (Plum et al., 2007) 
were reported in literature. Therefore, their corresponding inhibitors were applied 1 h 
prior to leptin treatment in order to figure out the potential responsible signaling path-
ways for angulin-1 downregulation induced by leptin. JAK2 was supposed to be the 
upstream pathway but in both T84 and Caco-2 cells its inhibitor AG490 only partially 
blocked the decrease of angulin-1 (Figure 22a, b, *p < 0.05, n = 6). STAT3 inhibitors 
Stattic and WP1066 on the other hand could completely inhibit this effect in both cell 





Figure 22 Densitometric analysis of angulin-1 expression pre-treated with dif-
ferent inhibitors in T84 cells (a) and in Caco-2 cells (b). JAK2 inhibitor AG490 
was able to partially restore the expression of angulin-1 (*p < 0.05, n = 6). 
STAT3 inhibitors Stattic and WP1066 block the downregulation of leptin (***p 
< 0.001, n = 6, respectively). ERK1/2 inhibitor U0126 and PI3K inhibitor 




Next, phosphorylation protein analysis was performed in order to further illuminate 
STAT3 regulation. A significant change of STAT3 phosphorylation was observed after 
30 min incubation with leptin in T84 cells (Figure 23a, **p < 0.01, n = 7) and in Caco-
2 cells (Figure 23b, **p < 0.01, n = 6) and peaked after 60 min of leptin treatment in 
T84 cells (Figure 23a, ***p < 0.001, n = 11) and in Caco-2 cells (Figure 23b, **p < 
0.01, n = 9).  
 
 
Figure 23 Phosphorylated STAT3 to total STAT3 ratio at different time points 
of leptin treatment in T84 (a) and Caco-2 cells (b). The phosphorylation of 
STAT3 reached significancy after 30 min of leptin treatment and peaks at 60 




With 1 h of pre-incubation with JAK2 inhibitor AG490, a partial blockage of STAT3 
phosphorylation was demonstrated in T84 cells (Figure 24a, **p < 0.01, n = 8) and in 
Caco-2 cells (Figure 24b, *p < 0.05, n = 6). Akin to the inhibitors finding on angulin-1 
protein expression, the phosphorylation of STAT3 was fully inhibited by the treatment 
of Stattic or WP1066 in both cell lines (Figure 24a, b, ***p < 0.001, n = 6 - 8). 
 
 
Figure 24 Effect of inhibitors on phosphorylated STAT3 to total STAT3 ratio 
in T84 (a) and in Caco-2 cells (b). The phosphorylation of STAT3 was reduced 
to leptin-free condition after the application of Stattic or WP1066 (***p < 0.001, 
n = 6, respectively). AG490 was only able to incompletely inhibit STAT3 path-
way. *p < 0.05, **p < 0.01, ***p < 0.001, n = 6 – 8. 
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4.2 Potential role of tricellulin in remission of UC 
4.2.1 Patients features 
From 2017 to 2020, 14 UC patients and 24 controls (patients without intestinal dis-
eases who had colonoscopy examination) were enrolled to the project (Table 2). The 
diagnosis of UC follows the latest guideline Ungaro et al. (2017). In total, 36 pieces of 
biopsies were collected from the 14 UC patients from different time of follow-up. The 
Mayo endoscopic subscore was used to evaluate disease activity (Schroeder et al., 
1987). Remission of UC was defined according to the clinical presentation and to the 
normal Mayo endoscopic subscore while active patients were those with mild, moder-
ate, or severe disease activity. 
Table 2 Characteristics of the enrolled patients 
Characteristic Control (n = 24) UC (n = 14) 
Age (median, range) 54 (24-66) 50 (35-60) 
Gender (male/female) 8/16 5/9 
Mayo endoscopic subscore (n)   
normal - 10 
active - 4 
 
4.2.2 Tricellulin expression in remission of UC 
Using the collected biopsies, the expression of tricellulin along with several other TJ 
proteins was analysed on both mRNA and protein level. First, on mRNA expression 
level, tricellulin in remission patients of UC (UCRem) was not changed compared with 
controls (Ctrl) (Figure 25a), consistent with a recent research from Kjæ rgaard et al. 
(2020). Previous study investigated claudin-2 (Cldn-2) and claudin-4 (Cldn-4) protein 
expression in active patients of UC (Krug et al., 2018), thus here the mRNA expression 
level of these two proteins was also analysed in order to be comparable. In UCRem, 
Cldn-2 and Cldn-4 mRNA expression were unaltered in comparison with Ctrl (Figure 
25b, c). As for the other component of the tTJ, the angulin family (angulin-1, -2, -3) 
which played a role in CD without alteration of tricellulin expression (Hu et al., 2020) 









Figure 25 Scatterplot with bar of mRNA expression analysis of TJ proteins in 
human colon biopsies. Mean value of Ctrl was set to 100 %. (a) Tricellulin: 
Ctrl = 100 ± 16.75 %, n = 22, UCRem: 99.25 ± 14.37 %, n = 28. (b) Cldn-2: Ctrl 
= 100 ± 18.61 %, n = 19; UCRem = 89.66 ± 26.37 %, n = 24. (c) Cldn-4: Ctrl = 
100 ± 28.64 %, n = 20; UCRem = 97.58 ± 20.27 %, n = 28. (d) Angulin-1: Ctrl 
= 100 ± 16.81 %, n = 22; UCRem = 116.13 ± 27.89 %, n = 24. (e) Angulin-2: 
Ctrl = 100 ± 21.85 %, n = 24; UCRem = 67.14 ± 10.88 %, n = 29. (f) Angulin-3: 
Ctrl = 100 ± 27.54 %, n = 20; UCRem = 165.79 ± 39.05 %, n = 27. 
 
Next, on protein expression level, tricellulin in UCRem was at the same range as in Ctrl 
while in active UC (UCActive) was downregulated, similar to previous finding (Krug et al., 
2018) (Figure 26a, b, **p < 0.01). Cldn-4 in UCRem also did not change compared with 
Ctrl while the tendency of reduction in UCActive was in line with the downregulation in 
previous study (Oshima et al., 2008, Krug et al., 2018) (Figure 26c, d). Furthermore, 







Figure 25 Analysis of TJ proteins expression in human colon biopsies. Mean 
value of Ctrl was set to 100 %. (a) Scatterplot with bar of tricellulin of Ctrl, 
UCRem and UCActive. Tricellulin of UCRem retained the same level compared to 
Ctrl, while in UCActive tricellulin was downregulated compared to both UCRem 
and Ctrl (Ctrl: 100 ± 4.75 %, n = 23; UCRem: 100.69 ± 4.79 %, n = 30; UCActive: 
60.22 ± 5.47 %, n = 6, **p < 0.01). (b) Representative western blots of tricel-
lulin from Ctrl, UCRem and UCActive. (c) Scatterplot with bar of Cldn-4 of Ctrl 
(100 ± 8.70 %, n = 16), UCRem (107.63 ± 20.06 %, n = 16) and UCActive (46.89 
± 9.03 %, n = 6). (d) Representative western blots of Cldn-4 from Ctrl, UCRem 
and UCActive. (e) Scatterplot with bar of angulin-1 of Ctrl (100 ± 17.32 %, n = 
12) and UCRem (108.01 ± 19.58 %, n = 12). (f) Representative western blots 
of angulin-1 from Ctrl and UCRem. 
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4.2.3 Electrophysiological properties of colon biopsies in remission of UC 
Regarding the intestinal barrier function, impedance spectroscopic analysis of the bi-
opsies exhibited an unchanged transepithelial resistance in UCRem compared with Ctrl 
(Figure 27a). Permeability for fluorescein was also at the same level as in UCRem in 
comparison with Ctrl (Figure 27b), consistent with the previous finding that permeabil-
ity for 400 Da FITC-sulfonic acid was comparable to Ctrl (Vivinus-Nébot et al., 2014). 
Permeability for macromolecule represented by FD4 in UCRem remained unaltered 
compared to Ctrl as well (Figure 27c). 
As for UCActive, transepithelial resistance (Rt) was within a similar range as in UCRem 
and Ctrl, wherein the epithelial resistance (Repi) was reduced and the subepithelial re-
sistance (Rsub) tended to raise (Figure 27a, *p < 0.05). Permeability for both fluores-
cein and FD4 was increased compared with Ctrl and UCRem (Figure 27b, c, ***p < 






Figure 27 Electrophysiological and functional analysis of intestinal biopsies 
in Ctrl, remission and active UC. (a) Electrical resistances of colon biopsies 
of Ctrl, remission UC (UCRem), and active UC (UCActive). UCRem showed the 
same level of transepithelial resistance (Rt), epithelial (Repi) and subepithelial 
resistance (Rsub) as in Ctrl (Ctrl: Rt = 37.89 ± 3.02 Ω · cm2, Repi = 30.62 ± 3.79 
Ω · cm2, Rsub = 7.26 ± 0.85 Ω · cm2, n = 5; UC Rem: Rt = 41.08 ± 2.65 Ω · cm2, 
Repi = 31.45 ± 2.53 Ω · cm2, Rsub = 9.63 ± 1.03 Ω · cm2, n = 14). UCActive has 
lower Repi (17.8 ± 2.53 Ω · cm2, n = 3) compared with Ctrl (*p < 0.05) and 
UCRem (*p < 0.05), together with an increasing tendency of Rsub (14.29 ± 2.69 
Ω · cm2, n = 3) leading to the same level of Rt (32.09 ± 7.00 Ω · cm2, n = 3). 
(b) Permeability for fluorescein. In Ctrl and UC Rem, the permeability stayed at 
the same range, both of which are lower than UCActive (Ctrl: 3.15 ± 1.09 · 10-6 
cm · s-1, n = 8; UC Rem: 4.82 ± 0.65 · 10-6 cm · s-1, n = 11; UCActive: 12.29 ± 
1.53 · 10-6 cm · s-1, n = 6, ***p < 0.001). (c) Permeability for FITC-dextran 4 
kDa. Similar results were observed that UCActive had higher permeability than 
Ctrl and UC Rem (Ctrl: 3.10 ± 0.87 · 10-6 cm · s-1, n = 8; UC Rem: 2.81 ± 0.57 · 10-




4.3 AP-1-involved IL-13-mediated tricellulin downregulation in UC 
4.3.1 Recognition of potential AP-1 binding sites involved 
Based on the previous investigation that sub-proteins of AP-1, Jun and Fos family pro-
teins, were involved in IL-13-mediated tricellulin downregulation in UC (Krug et al., 
2018), potential binding sites of these two protein families were searched in an online 
database ISMARA (Integrated System for Motif Activity Response Analysis) (Balwierz 
et al., 2014) and literature (Van Lint et al., 1991, Hess et al., 2004, Ji et al., 2012, Gray 
et al., 2012, Kim et al., 1997, Carroll et al., 2006), then recognised on a region of   
5.1 kbp upstream of the start codon of tricellulin, assuming that this region might cover 
the whole or most important regions of the tricellulin promoter, with the focus on Jun 
and Fos (Figure 28a).  
Next, in attempts to facilitate the following experiments, the 5114 bp tricellulin promoter 
was shortened to 3925 bp (Figure 28b). In addition, a 2189 bp-length promoter that 
did not contain Jun or Fos motif of higher affinity was also constructed in order to pre-
liminarily screen whether these binding sites should be analysed in more detail (Figure 
28c). All three promoters were inserted onto a firefly luciferase vector pGL4.10 and 
then transiently transfected to human intestinal epithelial cell line HT-29/B6 which was 
used in previous research (Krug et al., 2018), along with a Renilla luciferase vector 
pGL4.19 served as an internal control of the system. However, the firefly luciferase 
value of both shortened promoters was much lower than the 5114 bp version as well 
as the empty vector while the Renilla luciferase values were relatively comparable 
(Figure 28d), indicating that although all three promoters were able to transcript, there 
were important factors, for example enhancers, missing on both shorter promoters. 







Figure 28 Schematic representation of AP-1 binding sites on tricellulin pro-
moter of 5114 bp (a), 3925 bp (b), and 2189 bp (c). (d) Respective firefly and 
Renilla luciferase values of different conditions.  
 
To create a system that properly reflected the change of tricellulin promoter induced 
by IL-13, the WT promoter was transfected in parallel on 12-well plate or Millicell-PCF 
inserts, followed by a 48-h treatment with IL-13. Although the protein expression of 
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tricellulin was downregulated in both conditions, the promoter activity could only be 
reduced when the cells grow on the inserts (Figure 29, ***p < 0.001, n = 11). Thus, the 
following experiments were performed with this setting. 
 
Figure 29 Tricellulin promoter activity in different transfection conditions. Af-
ter 48 h of IL-13 treatment, the promoter activity of the cells grown on 12-well 
plate remained unchanged (100.96 ± 2.88 %, n = 6) while the cells cultured 
on the Millicell insert decreased to 62.16 ± 3.71 % (***p < 0.001, n = 11). 
 
4.3.2 Tricellulin promoter activity in each mutation condition 
To further investigate the function of Jun and Fos binding site, tricellulin promoter con-
taining Jun, Fos, or both mutated binding sites (Figure 30a) were constructed and 
integrated into the vector pGL4.10. After 48 h of IL-13 treatment, promoter activity 
showed a decrease in the wildtype promotor as well as the fos-mutated promotor (fos-
mut) with the prerequisite of a downregulated tricellulin protein expression (Figure 30b, 
***p < 0.001). In addition, no reduction was observed when the jun binding site was 
mutated, but interestingly, despite different degrees, tricellulin promoter activity was 






Figure 30 (a) Schematic representation of jun- and fos-motif domain se-
quence of each tricellulin promoter mutant. WT = wild type. (b) Effects of mu-
tated binding sites on tricellulin promoter activity. The mean value of IL-13 
free condition in each mutation was set to 100 %. Untransfected Ctrl: 100.64 
± 2.61 %, Vector: 99.49 ± 1.88 %, WT: 62.16 ± 3.71 %, jun-mut: 102.21 ± 
3.75 %, fos-mut: 66.22 ± 2.35 %, double-mutation (DM): 82.26 ± 4.40 %, n = 
7 – 12, **p < 0.01, ***p < 0.001. 
 
4.3.3 Effects of additional c-jun and c-fos on tricellulin promoter activity 
According to the finding of Krug et al. (2018), within jun and fos protein family, c-jun 
and c-fos were likely to be involved in tricellulin downregulation. Therefore, to clarify 
the potential role of jun or fos binding site, additional co-transfection was performed 
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with human c-jun and human c-fos plasmid. No significant change of tricellulin pro-
moter activity was observed after additional transfection of jun, fos, or jun plus fos 
(Figure 31). 
 
Figure 31 Tricellulin promoter activity with co-transfection of jun, fos, or jun 
plus fos. The mean value of IL-13 free condition in each mutation was set to 
100 %. WT + IL-13: 62.16 ± 3.71 %, WT + IL-13 + jun: 65.69 ± 4.75 %, WT + 








5.1 The involvement of angulins in active CD 
The tTJ is the vertical ladder-like meshwork of TJ strands at the regions of where three 
or more cells encounter, which has been observed and described around fifty years 
ago (Staehelin et al., 1969). Because of the special tube-like structural arrangement, 
the tTJ has been assumed to be the weak spot of the paracellular barrier for a long 
period of time. 
However, the first molecular component of the tTJ, tricellulin, was not discovered until 
2005 (Ikenouchi et al., 2005). Overexpression experiments to different levels showed 
that tricellulin formed a barrier at tTJs for macromolecules (Krug et al., 2009a). After-
wards, screening cDNA library of T84 cells by the fluorescence localization-based ret-
rovirus-mediated expression (FL-Rex) method revealed the second role of angulin-1 
(still named LSR back then) as a fundamental element of the tTJ and a recruiter of 
tricellulin to tTJs (Masuda et al., 2011). Two years later, the examination of the other 
two homologues of angulin-1, angulin-2 and -3 (ILDR1 and ILDR2 at the time), com-
pleted the present composition of the tTJ as well as the angulin family (Higashi et al., 
2013). 
The localization of angulins at tTJs was exhibited by immunofluorescent staining of the 
mouse epithelial cell line EpH4 as well as in mouse tissues, and further evidenced by 
its presence along the central tube using immuno-freeze-fracture replica electron mi-
croscopy (Masuda et al., 2011, Higashi et al., 2013). In principle, at least one angulin 
shows expression in the tissues where tricellulin is expressed. In the colon, this role 
falls on angulin-1 (Higashi et al., 2013).  
In a previous study, the tricellulin protein expression level was found to be unchanged 
in sigmoid colon biopsies of CD patients compared with controls, while the localization 
of tricellulin interestingly exhibited a shift from crypts towards surface epithelium (Krug 
et al., 2018). This variation in localization indicated the complex involvement of the 
upstreaming regulators of tricellulin in CD. Therefore, in this thesis, the expression 
level of angulins was analysed in CD. Firstly, the analysis of FFPE sections from CD 
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and controls revealed a downregulation of angulin-1 in CD. Then, to exclude the po-
tential influence from the samples which has been fixed and embedded, fresh endo-
scopic biopsies from controls, active and remission CD were analysed. The expression 
of angulin-1 was also downregulated in active CD compared to controls and addition-
ally this decrease was shown to be recovered in remission of CD. Meanwhile, the com-
parison at mRNA level also returned similar results, indicating that at least the main 
form of angulins in colon, angulin-1, was involved in the complex regulation of tTJ pro-
teins in CD. Unfortunately, limited by the insufficient reliability of the antibodies availa-
ble in the laboratory against angulin-2 and -3, only the mRNA expression level of these 
two proteins was analysed here.  
As lack of all three angulins led to the deviation of tricellulin from tTJs and a strong 
reduction of TER and a sharp rise of permeability to fluorescein (332 Da), FITC-dextran 
4, 10, and 40 kDa (Masuda et al., 2011, Higashi et al., 2013), further examination re-
garding to barrier function in CD needs to be performed. 
5.2 Leptin affecting the expression of angulin-1 
In the exploration of the underlying mechanisms behind angulin-1 downregulation in 
CD, leptin was revealed to be the only one that could induce this effect in human in-
testinal epithelial cell lines T84 and Caco-2 among the tested twelve cytokines com-
monly involved in CD. The pathophysiological role of leptin is twofold: (i) leptin could 
enhance the effect of cytokines from Th1 and Th17 families and (ii) the hypertrophic 
MAT in CD could serve as an extra source of leptin releasement (Weidinger et al., 
2018). 
Regarding the localization of tricellulin in T84 and Caco-2 cells, no shift was observed 
by immunofluorescent staining, which appeared to be contradictory at first glance to 
the previous finding that tricellulin was not concentrated at tTJs after knockdown of 
angulin-1 (Masuda et al., 2011). However, on one hand, that knockdown was to an 
extreme extent of trace level of angulin-1 while the downregulation of angulin-1 caused 
by leptin was within the range of 40 to 50 percent. On the other hand, the previous 
experiment was performed using a cell line which did not express either angulin-2 or -
3, but these two proteins that were also able to recruit tricellulin (Higashi et al., 2013) 
were present in both T84 and Caco-2 cells. Therefore, the unshifted localization of 
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tricellulin was also reasonable. Although tricellulin was still localized at tTJs, the barrier 
function already became vulnerable as an increased permeability for FD4 in Caco-2 
cells was observed, which was also in consistent with the previous finding that although 
angulin-2 and -3 could still hold tricellulin in position, but the barrier function could not 
be fully recovered (Higashi et al., 2013). Further investigation of these two proteins is 
needed but waits for antibodies of assuring quality to provide expression and localiza-
tion information. 
The functional differences between T84 and Caco-2 cells could be due to the different 
basic permeability for FD4. In Caco-2 cells, permeability for FD4 after leptin treatment 
was increased to the untreated level of T84, which might imply the maximum increase 
ability under the current conditions. This effect of impaired tTJ might be enlarged in a 
highly balanced circumstance as in vivo than in the experimental simplified cell culture 
models. 
Furthermore, the interaction between tTJ proteins which might be potentially reduced 
and subsequently vulnerate the barrier, for example tricellulin-tricellulin or tricellulin-
angulin interaction, could also not be directly visualized so far and needs exploration 
in the future. 
5.3 Leptin-regulated downregulation of angulin-1 via STAT3 pathway 
The signaling of leptin involves three isoforms of leptin receptor (LR). Due to lack of 
intrinsic kinase activity, the leptin signal requires the binding of Janus kinase (JAK) 2 
to form LR/JAK2 complex and phosphorylate certain tyrosine sites in order to trans-
duce (Myers et al., 2008). The long isoform of LR is the only isoform composed of three 
tyrosine phosphorylation sites, Tyr986, Tyr1079 and Tyr1141 in human (Schaab and 
Kratzsch, 2015) or Tyr985, Tyr1077 and Tyr1138 in rodents (Hekerman et al., 2005), which 
makes it the one of the most importance. 
There are numbers of pathways reported for the leptin signal. ERK pathway could be 
activated by Src-homology-2 domain protein (SHP-2) after binding to Tyr985 and then 
regulate the message of c-fos (Banks et al., 2000). The STAT5 pathway is stimulated 
via Tyr1077 or Tyr1138 and plays a role in reproduction (Hekerman et al., 2005). The 
STAT3 pathway could be triggered through Tyr1138, which subsequently could be pro-
hibited by suppressor of cytokine signaling 3 (SOCS3) after interacting with Tyr985 
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(Bjorbak et al., 2000) or JAK2 itself (Sasaki et al., 2000). Moreover, the PI3K pathway 
was connected to energy consumption in the central nerve system (Plum et al., 2007). 
In this thesis, the signaling of leptin were investigated by applying corresponding in-
hibitors of reported pathways. The cells pre-treated with JAK2 inhibitor AG490 or 
STAT3 inhibitors Stattic and WP1066 demonstrated the blockage of angulin-1 down-
regulation to a different extent. Phosphorylation assay disclosed the activation of 
STAT3 when treated with leptin. What is in common in these two experiments was the 
partial blockage of AG490 but total hindrance of Stattic and WP1066, indicating the 
dispensability of JAK2 (Figure 31). 
 
Figure 31 Scheme of the leptin-STAT3 pathway. Each side of the dashed line 
represents one access of STAT3 activation with or without binding of JAK2 




In HT-29/B6 cells, leptin was not able to downregulate angulin-1, indicating the involve-
ment of other potential indispensable factor(s) in this regulation, or change of the pro-
tein expression of the other two angulins. However, this was impossible to analyse due 
to present the lack of reliable antibodies.  
5.3 Recovered tricellulin expression and barrier function in remis-
sion UC 
UC is a chronic relapsing and remitting inflammatory disease, the cause of which has 
been assumed to be the consequence of the miscommunication between the immune 
system and the intestinal barrier. Tricellulin, a tTJ protein involved in barrier function, 
could serve as a potential messenger in between due to its liability for the passage of 
macromolecules.  In active UC, tricellulin was shown to be downregulated which was 
paralleled by an increased paracellular passage of macromolecules compared with 
control patients (Krug et al., 2018).  
These findings imply a possibility to explore the pathogenesis of UC by combing 
through the causal relation between tricellulin and the impaired barrier function. This 
also raised the classical hen-or-egg question regarding the initiation of the inflamma-
tion in UC. In active inflammatory condition, downregulation of tricellulin resulted in a 
defected TJ structure and an increased uptake of luminal antigens. Therein, it remains 
to be determined the role of tricellulin, as an initiation factor or as the consequence of 
the inflammation. Analysis of tricellulin as well as barrier function in inflammation-free 
condition of UC patients might provide a chance to answer this question. 
For this purpose, colon tissues from UC patients in remission and controls were col-
lected in this thesis. The mRNA and protein expression of tricellulin which were down-
regulated in active of UC were both recovered in remission patients. These results 
were consistent with a recent study of quiescent UC that tricellulin was at the same 
level as in controls (Kjæ rgaard et al., 2020). Previously, Cldn-4 was shown to be de-
creased as well in active UC (Oshima et al., 2008).  Here, a tendency of Cldn-4 down-
regulation was pointed out, but because of a rather low number of biopsies, this change 
was not significant. As for Cldn-4 in remission of UC, the expression remained at the 
same level as in controls. Additionally, the mRNA expression of Cldn-2 was investi-
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gated and demonstrated a similar level in remission of UC compared to controls. Un-
fortunately, all three Cldn-2 antibodies currently available failed to recognize Cldn-2 in 
human tissue as the antibodies did not identify signals from active patients that served 
as positive controls for Cldn-2 upregulation. For that reason, only mRNA expression of 
Cldn-2 was analysed.  
Regarding angulins, the mRNA expression of all three angulins was not altered in re-
mission of UC in comparison with controls. Angulin-1, the major constituent in colon of 
the angulin family (Higashi et al., 2013) and downregulated factor in CD (Hu et al., 
2020), demonstrated an unchanged protein expression level in remission UC. As writ-
ten in 5.1, the protein expression of angulin-2 and -3 was not investigated due to lack 
of reliable antibodies. 
Meanwhile, the electrophysiological features and paracellular fluxes of the collected 
biopsies were measured in Ussing chambers. Similar to a previous study (Krug et al., 
2018), epithelial resistance was reduced in active UC patients along with enhanced 
paracellular fluxes of fluorescein and FD4. In remission of UC, epithelial resistance, 
subepithelial resistance, and the overall transepithelial resistance were all within the 
same range as in controls.  The permeabilities for fluorescein and FD4 were also un-
changed, indicating that the barrier function in remission patients was also recovered. 
Taken together, tricellulin expression as well as the permeability for macromolecules 
up to 4 kDa was recovered in remission of UC, by which an ongoing antigen uptake 
causing the relapse of inflammation could not be verified. The exploration of the rela-
tion between tricellulin and the passage of macromolecules in the pathophysiology of 
UC therefore requires further investigation at more precise time points, for instance 
shortly before the relapse. However, until now neither the first onset nor the relapse of 
UC is predictable, which raises the need for long-term follow-up studies to obtain suit-
able tissues in order to detect a novel predictive factor for relapse.  
5.4 c-jun as one main mediator of tricellulin downregulation in active 
UC 
AP-1 was shown to be the common downstreaming transcription factor of JNK and 
ERK1/2 signaling pathways which were responsible for IL-13-induced tricellulin down-
regulation (Krug et al., 2018). Using the dual-luciferase reporter assay, we measured 
106 
 
the activity of tricellulin promoter with or without potentially mutated AP-1 binding 
site(s), which rendered interesting results. 
The involvement of jun binding site could be confirmed by the fact of unchanged tricel-
lulin promoter activity after IL-13 treatment when this site alone was mutated. The sole 
mutation of the fos motif had no influence on tricellulin promoter activity regulated by 
IL-13. This indicated that IL-13-induced tricellulin downregulation proceeded via the 
jun binding site, and that although AP-1 could bind to tricellulin promoter via fos in 
absence of the jun motif, the promoter activity was affected by IL-13 treatment. Sur-
prisingly however, the mutation of both jun and for sites together did not lead to un-
changed promoter activity as one would expect, because the jun site was mutated here, 
too. 
One explanation for this could be that the other AP-1 binding motifs (as marked in 
Figure 1), which were less specific for fos or jun were able to function when the pro-
moter lacks both higher affinitive jun and fos sites. It is possible that these sites bind 
to jun protein, despite relatively weaker, but could lead to signaling to a less extent. To 
explore this in more detail, all the remaining potential sites for AP-1 should be mutated 
and analysed. 
The regulation of AP-1 could draw into great complexity due to (i) the various combi-
nations of AP-1 subunits; (ii) the different binding affinity and specificity; (iii) the inter-
action with other regulators; and (iv) the diversity of expression and activity among 
individual cell types, which leads to the variation of abundance, stability, and activity of 
AP-1 and its component proteins (Landschulz et al., 1988, Karin et al., 1997, Behre et 
al., 1999, Meng and Xia, 2011). 
AP-1 is a dimeric structure mainly composed of jun and fos family proteins, however, 
activating transcription factor (ATF) family protein (Ziff, 1990), musculoaponeurotic fi-
brosarcoma (Maf) family protein (Nishizawa et al., 1989), neural retina leucine zipper 
(Nrl) (Swaroop et al., 1992, Kerppola and Curran, 1994), and Jun-dimerizing proteins 
(JDPs) (Aronheim et al., 1997) are also reported to form AP-1 dimers. For example, 
ATF family proteins were also shown to be involved in JNK (Wang et al., 2020, Zhou 
et al., 2020, Kashyap et al., 2019) and ERK1/2 pathways (Kitanaka et al., 2019, Buzzi 
et al., 2010, Du et al., 2019). This growing number of proteins known to be participated 
in the formation of AP-1 largely increases the number of possible combinations of AP-
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1 subunits and in addition the complexity of regulatory mechanisms. Therefore, with 
the absence of jun and fos binding sites, the possibility that these proteins are able to 
bind to DNA, which might have another structural orientation due the lack of the binding 
sites, and transduce signals, should not be neglected. 
Secondly, different dimer combinations of AP-1 lead to different binding preferences. 
Jun-Jun as well as Jun-Fos exhibits higher affinity for the phorbol 12-O-tetradecano-
ate-13-acetate (TPA)-responsive element (TRE), while Jun-ATF preferentially binds to 
the cyclic adenosine monophosphate (cAMP)-responsive element (CRE) (Hai and Cur-
ran, 1991). Other combinations are also able to interact with DNA sequences apart 
from these two common elements (Meng and Xia, 2011), which provides a further ex-
planation why the double-mutated tricellulin promoter showed a decreased activity. 
Besides the influence from the AP-1 protein family, interaction with external factors 
could also exert impact on transcription activity. An example for this is that Ras protein 
could upregulate c-Jun expression and enhance AP-1 activity by phosphorylating c-
Jun via JNK as well as inducing c-Fos transcription via ERK1/2 (Behre et al., 1999, 
Deng and Karin, 1994). Another example is the inhibitory effect caused by the physical 
interaction between leucine zipper domain of jun and the helix-loop-helix region of 
MyoD (Bengal et al., 1992). 
Furthermore, the regulation of AP-1 also involves the stability of jun and fos, repre-
sented by the increased stability and transcriptional activity of phosphorylated c-Jun 
by JNK (Musti et al., 1997, Smeal et al., 1994) and by the degradation of c-Fos resulting 
from the phosphorylation of c-Jun by various protein kinases like mitogen-activated 
protein kinase (MAPK) (Tsurumi et al., 1995). 
In addition, the result that the promoter assay did not work on 12-well plates but only 
on cell inserts in spite of tricellulin downregulation (Figure 32) might imply a complex 
regulation downstream of IL13Rα2 itself. The cell inserts could provide the condition 
for directional growth by allowing access and exchange of media solutes from the basal 
site, indicating that a proper cellular polarity in the regulation of the AP-1- and IL-13-





Figure 32 Tricellulin expression in different transfection conditions. After 48 
h of IL-13 treatment, tricellulin was downregulated both on 12-well plates 
(75.25 ± 7.93 %, *p < 0.05, n = 3) and on the Millicell inserts (72.77 ± 9.78 %, 
*p < 0.05, n = 3). 
 
These findings suggest the possibility of using a jun motif-specific anti-peptide to block 
the binding of AP-1 via jun and hence the downregulation of tricellulin. On the other 
hand, to avoid the complexity as well as broad involvement of AP-1, further investiga-
tion targeting JNK pathway alone, but not ERK1/2 pathway, might also be promising. 
It is worth noting that both Cldn-2 upregulation and tricellulin downregulation effects 
induced by IL-13 are linked to JNK signaling, as shown in previous studies. There, the 
increase of Cldn-2 could be blocked by inhibitor U0126, which targets the upstreaming 
ERK1/2 of JNK, and that the decrease of tricellulin could be prevented by targeting 
JNK1/2/3 (Meng and Xia, 2011, Krug et al., 2018). However, one needs to keep in 
mind that all these factors, AP-1, ERK1/2, and JNK, are very common signaling pro-
teins involved in many regulatory processes and that inhibition of these therefore has 





The tight junction (TJ) protects the intestinal barrier function and controls the paracel-
lular transport of water, ions, small water-soluble molecules, and macromolecules. The 
structure of the TJ comprises the belt-like meshwork of the TJ strands between two 
epithelial cells, called the bicellular TJ (bTJ), and the vertically converged central tube 
by the most apical bTJs in the region where three or more cells meet, termed tricellular 
TJ (tTJ). The tTJ is assumed to be a weak spot of the intestinal epithelial barrier due 
to the presumed space left in the central tube. Major components of the tTJ are tricel-
lulin and the three members of the angulin family. Tricellulin regulates the passage of 
macromolecules and therefore acts a crucial part in preventing an uncontrolled uptake 
of pathogens and immunogens from the gut lumen. Angulin-1, -2, and -3 share the 
ability to recruit tricellulin to the tTJ. In each epithelium, at least one angulin localizes 
at the tTJ and in colon the major role falls on angulin-1. 
Dysregulation of TJ proteins could cause or could be caused by corresponding dis-
eases due to altered paracellular passage. Inflammatory bowel diseases (IBD) are 
possibly caused by a dysregulated communication between intestinal epithelial cells 
and the immune system. IBD has two major subtypes, Crohn’s disease (CD) and ul-
cerative colitis (UC). In CD, tricellulin was found to have a shifted localization with un-
altered expression level while in UC, it was downregulated by IL-13.  
In this thesis, several aspects dealing with the tTJ and the related regulation in IBD 
were investigated. 
First, the expression of angulin-1 was analysed in IBD. Angulin-1 was downregulated 
in active CD at both mRNA and protein expression levels. For the exploration of the 
mechanisms behind, three intestinal epithelial cell lines were investigated using cyto-
kines treatments, inhibitors treatments, phosphorylation analysis, and electrophysio-
logical and flux measurements. It turned out that leptin could induce the downregula-
tion of angulin-1 in T84 and Caco-2 cells, and that STAT3 and its upstreaming pathway 
JAK2 were responsible signaling mechanisms of this regulation. Incomplete blockage 
of STAT3 activation by the JAK2 inhibitor AG490 suggested an independent pathway 
bypassing JAK2. An observed increase of permeability for FITC-dextran 4 kDa (FD4) 
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in Caco-2 cells indicated the potency of macromolecular passage caused by angulin-
1 downregulation. Findings of this subproject have been published (Hu et al., 2020). 
In a second project, it was studied whether tricellulin might still be altered in remission 
of UC at expression level, which subsequently might increase potential antigen uptake 
and lead to relapse of the inflammation. Intestinal biopsies from patients in UC remis-
sion were analysed for the expression of tricellulin as well as for electrophysiological 
and flux properties. Tricellulin expression in remission UC was not significantly different 
to controls at both mRNA and protein expression levels. In line with this, transepithelial 
resistance, epithelial resistance, and subepithelial resistance were all similar between 
remission UC and healthy controls, along with the comparable permeability for fluores-
cein and FD4. Analysis of timepoints shortly before occurrence of relapse might show 
different expression. However, this remains a hypothesis and needs to be further elu-
cidated. 
A third project focused on the downregulation of tricellulin by IL-13 via AP-1. Promoter 
studies were performed to analyse the responsible binding sites for this downregulation. 
Mutation analysis found that the jun binding site – 3473 bp before the start codon – 
was essential for the regulation. 
In conclusion, several aspects of the tTJ proteins in IBD were studied and lead to new 





Die Tight Junction (TJ) gewährleistet die intestinale Barrierefunktion und reguliert den 
parazellulären Transport von Wasser, Ionen, kleinen Soluten und Makromolekülen. 
Die Struktur der TJ besteht aus der bizellulären TJ (bTJ), dem gürtelartigen Netzwerk 
von Strängen zwischen zwei Epithelzellen, und der trizellulären TJ (tTJ). Die tTJ bildet 
einen vertikal konvergierenden „central tube“ von den apikalsten bTJs der Region, in 
der drei oder mehr Zellen aufeinandertreffen. Es wird angenommen, dass die tTJ eine 
potentielle Schwachstelle der intestinalen Barriere aufgrund ihrer röhrenartigen Struk-
tur darstellt. Tricellulin und die drei Mitglieder der Angulinfamilie sind die Haupt-Pro-
teinbestandteile der tTJ. Tricellulin reguliert in reziproker Weise die Passage von Mak-
romolekülen und spielt dadurch im Darm eine entscheidende Rolle bei der Verhinde-
rung der unkontrollierten Aufnahme von Antigenen aus dem Lumen. Die Angulin-1, -2 
und -3 besitzen die Fähigkeit, Tricellulin zur tTJ zu rekrutieren. In allen tTJs ist min-
destens ein Angulin lokalisiert und im Kolon spielt Angulin-1 die Hauptrolle. 
Eine Dysregulation von TJ-Proteinen könnte entsprechende Erkrankungen aufgrund 
einer veränderten parazellulären Passage verursachen oder durch diese verursacht 
werden. Chronisch-entzündliche Darmerkrankungen (CED) werden möglicherweise 
durch eine dysregulierte Kommunikation zwischen Darmepithelzellen und dem Im-
munsystem verursacht. Die zwei Haupttypen der CED sind Morbus Crohn (MC) und 
Colitis ulcerosa (CU). Bei MC wurde eine veränderte Lokalisation von Tricellulin bei 
unverändertem Expressionsniveau gefunden, während es bei CU durch Interleukin-13 
(IL-13) in der Expression herunterreguliert wurde.  
In dieser Arbeit wurden verschiedene Aspekte, die sich mit der tTJ und der damit rele-
vante Regulierung in der CED befassen, untersucht. 
Zunächst wurde die Expression von Angulin-1 bei CED analysiert. Angulin-1 wurde in 
der aktiven MC sowohl auf mRNA- als auch auf Proteinexpressionsebene herunterre-
guliert. Zur Erforschung der zugrunde liegenden Mechanismen wurden drei Darme-
pithelzelllinien verwendet, wobei Zytokin- und Inhibitorbehandlungen, Phosphorylie-
rungsanalysen sowie Elektrophysiologische- und Fluxmessungen durchgeführt wur-
den. Es stellte sich heraus, dass Leptin die Herunterregulierung von Angulin-1 in T84- 
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und in Caco-2-Zellen induzieren konnte und dass STAT3 und sein Upstream-Signal-
weg JAK2 für die Signalmechanismen dieser Regulation verantwortlich waren. Die un-
vollständige Blockierung der STAT3-Aktivierung durch den JAK2-Inhibitor AG490 deu-
tete auf einen unabhängigen Signalweg hin, der JAK2 umgeht. Ein beobachteter An-
stieg der Permeabilität für FITC-Dextran 4 kDa (FD4) in Caco-2-Zellen zeigte die Po-
tenz der makromolekularen Passage an, die durch die Herunterregulierung von Angu-
lin-1 verursacht wird. Die Ergebnisse dieses Teilprojekts wurden publiziert (Hu et al., 
2020).  
In einem zweiten Projekt wurde untersucht, ob Tricellulin bei der Remission von CU 
auf Expressionsebene noch verändert sein könnte, und ob die potenzielle Antigenauf-
nahme anschließend erhöht und durch die einem Schub der Entzündung verursacht 
wird. Darmbiopsate von Patienten in Remission einer CU wurden auf die Expression 
von Tricellulin sowie mittels elektrophysiologischen und Fluxmessungen untersucht. 
Die Expression von Tricellulin in Remission der CU war sowohl auf mRNA- als auch 
auf Proteinexpressionsebene nicht signifikant von gesunden Kontrollen verschieden. 
Dementsprechend waren der transepitheliale Widerstand, der epitheliale Widerstand 
und der subepitheliale Widerstand zwischen Remission der CU und gesunden Kon-
trollen ähnlich, ebenso wie die Permeabilität für Fluorescein und für FD4. Zeitpunkte 
kurz vor dem Schub konnten im Rahmen dieser Arbeit nicht untersucht werden. Ob 
sich zu diesem Zeitpunkt unterschiedliche Ausprägungen zeigen, muss daher noch 
aufgeklärt werden. 
Ein drittes Projekt konzentrierte sich auf die bereits beschriebene Herunterregulierung 
von Tricellulin durch IL-13 über AP-1. Um die verantwortlichen Bindungsstellen für 
diese Herunterregulierung zu analysieren, wurden Promotorstudien durchgeführt. Mu-
tationsanalysen ergaben, dass die jun-Bindungsstelle – 3473 bp vor dem Startcodon 
– für die Regulation wichtig war. 
Zusammenfassend ist zu sagen, dass mehrere Aspekte der tTJ-Proteine bei der CED 
untersucht wurden und zu neuen Erkenntnissen führten, die als Grundlage für eine 
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DC dendritic cell 
DLR dual luciferase reporter 
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FFPE formalin-fixed paraffin-embedded 
FITC fluorescein isothiocyanate 
GWAS genome-wide association studies 
HRP horseradish peroxidase 
IBD inflammatory bowel disease 
IFN interferon 
Ig-like immunoglobulin-like domain 
IHC immunohistochemistry 
IL interleukin 
IL-13Rα2 IL-13 receptor alpha 2 
IL-4Rα IL-4 receptor α 
ILC innate lymphoid cell 
ILDR1 immunoglobulin-like domain-containing receptor 1 (= angulin-2) 
ILDR2 immunoglobulin-like domain-containing receptor 2 (= angulin-3) 
ISMARA Integrated System for Motif Activity Response Analysis 
JAK Janus kinase 
JAM junctional adhesion molecule 
JDP Jun-dimerizing protein 
JNK c-Jun N-terminal kinase 
kDa kilodalton 
LB lysogeny broth 
LPMC lamina propria mononuclear cell 
LR leptin receptor 
LSR lipolysis-stimulated lipoprotein receptor (= angulin-1) 
Maf musculoaponeurotic fibrosarcoma 
MAPK mitogen-activated protein kinase 
MARVEL myelin and lymphocyte and related proteins for vesicle trafficking and  
membrane link  
 (MARVEL D2 = tricellulin) 
MAT mesenteric adipose tissue 
MEM minimum essential medium 
MHC major histocompatibility complex 
Mv microvillus 
NK natural killer cell 
nm nanometer 
Nrl neural retina leucine zipper 
OCEL occludin ELL-like domain 




PVDF polyvinylidene fluoride 
PVP polyvinylpyrrolidone 
Repi epithelial resistance 
RPMI Roswell park memorial institute 
Rsub subepithelial resistance 
RT-PCR real-time PCR 
SAT subcutaneous adipose tissue 
SDS sodium dodecyl sulfonate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SEM standard error of the mean 
SHP-2 Src-homology-2 domain protein 
SMR standardized mortality ratio 
SOCS3 suppressor of cytokine signaling 3 
STAT signal transducer and activator of transcription 
TAE tris-acetate/EDTA 
TAMP TJ-associated MARVEL protein 
TBS tris-buffered saline 
TEMED tetramethyl ethylenediamine 
TER transepithelial resistance 
Th T helper 
TJ tight junction 
TLR toll-like receptor 
TNF tumor necrosis factor 
TPA 12-O-tetradecanoate-13-acetate 
TRE TPA-responsive element 
Treg regulatory T cell 
tTJ tricellular tight junction 
UC ulcerative colitis 
UCActive active UC 
UCRem remission of UC 
UV ultraviolet 
VAT visceral adipose tissue 
WAT white adipose tissue 
WT wild type 
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